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ABSTRACT
ADAPTIVE INTERVENTIONS TREATMENT MODELLING AND REGIMEN
OPTIMIZATION USING SEQUENTIAL MULTIPLE ASSIGNMENT
RANDOMIZED TRIALS (SMART) AND Q-LEARNING
ABIRAL BANIYA
2018
Nowadays, pharmacological practices are focused on a single best treatment to
treat a disease which sounds impractical as the same treatment may not work the same
way for every patient. Thus, there is a need of shift towards more patient-centric rather
than disease-centric approach, in which personal characteristics of a patient or
biomarkers are used to determine the tailored optimal treatment. The “one size fits all”
concept is contradicted by research area of personalized medicine. The Sequential
Multiple Assignment Randomized Trial (SMART) is a multi-stage trials to inform the
development of dynamic treatment regimens (DTR’s). In SMART, a subject is
randomized through various stages of treatment where each stage corresponds to a
treatment decision. These types of adaptive interventions are individualized and are
repeatedly adjusted across time based on patient’s individual clinical characteristics and
ongoing performance. The reinforcement learning (Q-learning), a computational
algorithm for optimization of treatment regimens to maximize desired clinical outcome
is used in optimizing the sequence of treatments. This statistical model contains
regression analysis for function approximation of data from clinical trials. The model
will predict a series of regimens across time, depending on the biomarkers of a new
participant for optimizing the weight management decision rules.

xi
Additionally, for implementing reinforcement learning algorithm, as it is one of
the machine learning approach there should be a training data from which we can train
the model or in other words approximate the function, Q-functions. Then the
approximated functions of the model should be evaluated and after the evaluation they
should be further tested for applying the treatment rule to future patients. Thus, in this
thesis first the dataset obtained from Sanford Health is first restructured, to make it
conducive for our model utilization. The restructured training data is used in regression
analysis for approximating the Q-functions. The regression analysis gives the estimates
of coefficients associated to each covariate in the regression function. The evaluation
of model goodness-of-fit and fulfillment of underlying assumptions of simple linear
regression are performed using regression summary table and residual diagnostic plots.
As a two stage SMART design is put into practice, the Q-functions for these two stages
are needed to be estimated through multiple regression using linear model. Now, finally
after analyzing the fit adequacy the model is applied for prescribing treatment rules to
future patients. The prognostic and predictive covariates of new patient is acquired and
the optimal treatment rule for each treatment decision stage is assigned as the treatment
that results in maximum estimated values of Q-functions. The estimated values of each
regime were also computed using the value estimator function and regime that has the
maximum estimated value was chosen as optimal treatment decision rule.
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CHAPTER 1
INTRODUCTION
1.1 Background
On a daily basis decision makers or doctors play a vital role of
recommending treatments to patients in any kind of pharmacological practice [1].
Managing or treating a chronic illness generally involves a sequence of treatment
decisions in which factors such as response to previous treatments, severity of
symptoms and medicinal side-effects are to be taken under consideration while
deciding on if, when and how current treatment status needs to be altered.
Previously, these decisions were made based on identifying a single best treatment
for a particular disease, however, the clinical treatment design has begun to shift
towards more patient- centric approach rather than disease-centric one [2]. The
notion “Personalized Medicine” is based on the fact that two patients given the same
treatment may well respond differently or in other words a treatment that worked
for one patient may not work for the other. Further, Topol writes that “We have
entered a new era of medicine, in which each person can be near fully defined at
the individual level, instead of how we practice medicine at the population level
[3].” Therefore, Personalized Medicine underpins the posit that rather than direct
focus on disease diagnosis and treatment allocation, pharmacological practices
should aim towards more personalized approach which takes into account the
patient’s biomarkers or characteristics and these should dictate the treatment that
will work best for an individual.
As the personalized medical decision-making process is sequential and
involves careful assessment of patients’ individual characteristics and their ongoing
performance so that the nature of outcomes can be improved over time. Dynamic
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Treatment Regime (DTR) also known as adaptive interventions [4] or adaptive
treatment strategies [5] follows a sequential decision-making protocol comprising
of series of treatment decisions that take the current patient’s health information
and their past treatment history as inputs and outputs the time and procedure for
treatment alteration. Hence, the Adaptive treatment strategies (ATSs) are a vastly
expanding area of clinical research and is preferred as more formal means of
implementing personalized medicine. The strategy discussed in ATS is the
allocation of treatment at each sequential treatment decision point that depends
upon patient’s history of covariates and past treatments. In a simple scenario, we
can consider a single decision point rule where a patient is prescribed drug A if he
is overweight otherwise prescribed drug B. This scenario can occur in sequence at
each lengthy follow-up visit of the patient where treatment allocation decision is
undertaken each time. The follow-up visits can be considered as number of stages
in the DTR setting where in each stage the treatments are tailored to alterations in
patient’s characteristics and their response to previous treatments.
The ATS or DTR strategy involves multistage treatment decisions, thus we
need to design a multistage and sequential clinical trial for obtaining a high-quality
observational training dataset. Hence, a Sequential Multiple Randomized Trials
(SMART) design randomizes the treatments based on individual patient’s
biomarkers and clinical history at each stage of sequential decision-making process.
This design supports adaptive interventions that adapts to the system dynamics in a
multi-stage trial through a sequence of decision rules which dictate the intervention
path in order to maximize the long-term primary outcomes [6]. Using this SMART
design, researchers can collect or construct high quality training data which can
identify treatment allocation strategies that will eventually optimize patient’s health
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status. The concept of adaptive interventions mainly consists of two main
components:
•

Individualized interventions based on patient’s characteristics and
needs.

•

Interventions are time varying as they repeatedly adapt over time
responding to participants ongoing performance and varying needs.

Thus, we need an experimental setup with a sequence of decision rules
called DTR where patients covariates and treatment history are taken as input and
the recommended treatment decision rule is the output of the system. In this
experimental setup, the goal is to figure out the optimal sequential decision rule
described as one that maximizes the desirable clinical outcome. Approximate
dynamic programming and Q-learning a generalization reinforcement learning and
regression analysis technique with function approximation for obtaining an optimal
decision sequence in clinical interventions and services, are very popular as the
nature of clinical decision making is sequential. This reinforcement learning
method called Q-learning is particularly more appealing as it is easy to implement
and perhaps more importantly can be understood by non-statistical personals. The
algorithm involves learning an optimal regimen from patient’s data generated using
clinical reinforcement trial [7]. Q-learning involves approximating the Q-functions
defined by time indexed parameters of patients’ biomarkers that is obtained by
regression analysis at each intervention stage. The regression based approximation
of Q-function is implemented using linear model. In this model, the inputs are the
training data generated from SMART design and the outputs are the approximated
functions for potential final outcome. Finally, the optimal treatment policy or the
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potential final outcome is defined by the treatment sequence that maximizes these
Q-functions.
1.2 Literature Review
Reinforcement learning was introduced in pharmacological practice by
Pineu et al. (2007) to represent the concept of adaptive interventions by applying
hypothetical SMART study on alcohol dependence [8]. Pineau considered using
reinforcement learning for data analysis of studies that involved patients
randomized to multiple clinical trials, sequentially or more precisely SMART
designs. Similarly, in same year, Murphy et al. (2007, Neuropsychopharmacology)
suggested that Q-learning can be an important breakthrough for designing ATS and
constructing decision rules in chronic psychiatric disorders [9].
Further, Ma et al. in years of 2015 and 2016 published two different works
on establishing Personalized Treatment Rules in the field of oncology [10, 11].
First, they provided an overview on statistical methods to establish optimal
treatment rules for individualized medicine and also discussed examples in different
medical context, oncology being the emphasis. Various statistical inference
methods for identifying Individualized Treatment Rules (ITR) such as Multiple
Regression for Randomized Clinical Trial Data, Survival Analysis and methods for
observational data and high- dimensional biomarkers were introduced. Also, they
discussed some advanced methods of inference such as Robust Inference and data
mining using machine learning and the performances of these methods were
evaluated for ITR. Secondly, Ma et al. implemented Bayesian Predictive
Framework for integrating high-dimensional set of genomic features data with
clinical responses and treatment histories of patients. However, unsupervised
clustering with microevolutionary process was used which was very complicated as
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personalized medicine in field of oncology may have some limitation because of
the fact that biomarkers or characteristics obtained from small set of sample or panel
genes is never adequate to describe heterogeneity inherent to the diseases.
Between years 2011-14 Q- learning, a reinforcement learning algorithm,
has been a popular method for determining optimal treatment regimen operating
data generated from clinical trials assignment. In 2011, Zhao et al. implemented Qlearning for learning an optimal regimen using training data generated from clinical
trials assigned to patients with Non-Small Cell Lung Cancer [7]. The combination
of “clinical reinforcement trial” assignment for obtaining training dataset and
support vector regression for Q-function approximation were incorporated to
estimate optimal regimens that are individualized to patients’ subpopulation.
Although the simulation studies depicted small estimation bias while using sample
size 𝑁 ≥ 100, several challenges were faced in determining appropriate sample
size and learning generalization error for clinical reinforcement trial design.
In 2012, Shani and Moodie et al. performed two different experiments that
involved adaptive interventions, clinical trial assignments and treatment regimen
optimization. First, Shani et al. introduced Q-learning and the use of Q to indicate
the quality of given or chosen treatment [12]. They implemented Q-learning which
is a regression based function approximation method, with linear estimates to
prescribe adaptive interventions for children with ADHD and the training data was
obtained from ADHD SMART study (Center for Children and Families, SUNY at
Buffalo, William E. Pelham as PI). The operation of this learning algorithm was
illustrated for using in data from SMART design with different settings such as
SMART design with no embedded tailoring variables, re-randomization depending
upon intermediate outcomes, re-randomization depending upon an intermediate
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outcome and prior treatment. The advantages such as inclusion of both direct and
indirect effects during intervention stages, control for optimal-second stage
intervention while operating effects of first-stage interventions and reduced
potential bias of Q-learning over other regression based approach were also
discussed.
Furthermore, Moodie et al. implemented Q-learning and mentioned that it
is a popular method for estimating DTRs [13]. This reinforcement learning method
was used to examine the effects of breastfeeding on verbal cognitive ability and
growth of infant and it was based on observational data from Promotion of
Breastfeeding Intervention Trial. First, the authors discussed the use of Q-learning
according to different settings such as with multiple regression models, non-regular
settings and with observational dataset. Secondly, they discussed upon the
simulation study for comparison of performances using the Q-learning with certain
adjustments such as inclusion of (1) covariates as linear terms in Q-function, (2)
propensity score (PS) in Q-function (3) including quintiles of PS as covariates in
the Q-function and (4) Inverse Probability of treatment weights (IPTW). Finally, a
case study was presented on The Probit Study that analyzed the breastfeeding and
vocabulary test results. In this case study hospitals and other polyclinics that were
affiliated with Republic of Belarus were randomized to breastfeeding promotion
intervention model presented by WHO/UNICEF. The intervention or decision rule
suggested 98% infants, at age 6.5 months who were breastfed until 3 months scored
maximum in vocabulary and only 33% scored maximum who were breastfed until
6 months. Finally, it was concluded that Q-learning is an appealing method for
constructing DTR and recommended that the covariates in the model for Qfunctions should be directly included during function approximation process.
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Whereas if the relationships between input cofounders and outcome are not properly
understood than it is necessary to consider splines of polynomial functions to ensure
adequate model fit.
Conditional mean and variance modelling for smooth transformation of
data before applying non-smooth and nonmonotone operation of Q-function
approximation using regression analysis method was introduced by Laber et al. in
2014, for adequate fitting and well interpretable model [14]. In Q-learning the value
that maximized the second-stage Q-function or the optimal value is assigned as
potential optimal outcome for first-stage regression, this process is replaced by two
ordinary mean-variance function modeling described in Interactive model building
technique called IQ- learning. The model was implemented in Monte Carlo
simulations and Sequenced Treatment Alternatives to Relieve Depression
(STAR*D,2004) study that involved a sequentially randomized study of major
depressive disorder [15]. Although the process of defining contrast and main effect
functions for assigning optimal second stage outcome seems appealing, the
modelling of conditional distribution of these estimated contrast functions is
complicated and it may result as inadequate model subsequently.
Lastly, Schulte et al. in 2014 implemented Q and A learning methods to
estimate the optimal treatment regimens and the contrast between these two
statistical estimation methods was also discussed [16]. A-learning posits that the
entire Q-function is not needed to be defined for optimal regime estimation,
however, this statistical framework only requires the regression model representing
treatment contrasts and probability of a particular treatment being assigned to a
patient at each intervention given the patient information at these points. Further,
the simulation study was performed for one decision and two decision points and
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also applied to STAR*D study which involves four stages with each stage
consisting 12 weeks of treatment period. This study suggested that although Alearning is more robust to model misspecification than Q-learning but its
performance degrades when there are more than two treatment options at each stage
and the decision rules for defining optimal treatment regime is very complex. It is
also mentioned that Q-learning is more practical and more familiar to data analysts
as it consists preset of standard model diagnostic tools.
Therefore, in summary the above literature discussed different statistical
estimation methods such as IPTW, PS in Q-functions, A-learning including the
reinforcement learning approach of Q-learning and implemented them in medical
research such as ADHD studies, breastfeeding case-study, STAR*D study for
estimating optimal treatment regime. However, no such research or data analysis
has been done on weight management treatment plans and although there are some
limitations on operating Q-learning it seems more practical and adequate for
defining ATS. Similarly, the SMART design for obtaining training data is a
promising way for using this optimization algorithm as it defines sequential
decision making and randomizes treatment at each decision points so we can
observe the treatment that results maximum potential outcome or in other words
optimal treatment decision.
1.3 Motivation and Objectives
There is a need of an accurate mathematical model for trial assignment and
optimization of adaptive treatment strategies or personalized treatment regimens for
weight management plans in Sanford Profile.
The main objective of this research was to design a Sequential Multiple
Randomized Trial (SMART) for trial assignment to operate adaptive interventions
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and restructure the Sanford Profile weight management dataset per this design and
eventually use this dataset for implementing Q-learning, a reinforcement learning
algorithm that involves function approximation using regression analysis to
optimize the sequence of decision rules for personalized treatment. Thus, in order
to achieve this objective, the following tasks were performed:
1) Restructuring of Sanford Health Data on weight management according to
SMART design with two stages or decision points and two treatment
options at each of these points for preparing a training dataset with 210
observations.
2) Implementing Q-learning algorithm which involves regression analysis for
function approximation where input are the training data and output is the
approximated function for potential final outcome.
3) The regression summary at each stage is obtained which gives the estimated
coefficients of each independent predictor variables in approximated
regression function. It also provided the values of Residual Standard Error
which is the standard deviation of the residuals or error giving how close
the fit of regression line is to the points.
4) Graphical analysis was performed using regression diagnostics plots for
each stage regression to further analyze the fit adequacy and check
underlying assumption of applied regression model.
5) The optimization of adaptive decision rule was presented according to
maximum values of Q-functions and treatment resulting maximum Q-value
was assigned as optimal intervention rule.
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6) The regime value was estimated using weighted average of the outcomes
observed from patients in trial and the regime with maximum estimated
value was assigned as optimal treatment regime.
1.4 Organization of the Thesis
Chapter 1 provides the introduction on the subject and also background
about personalized medicine. Numerous literature that describes various models on
personalized healthcare are also described in this chapter. Also, the need of
mathematical model and optimization is explained in this chapter. Similarly,
Chapter 2 defines the theory behind the model and also provides the definition and
scopes of personalized medicine. In this chapter different framework such as
SMART design, reinforcement learning and statistical inference which are
implemented in the model are also described.
Chapter 3 defines the overall methodology for development of the model
which is further employed to prescribe personalized treatment rule. In this chapter
methods of acquiring training data, mathematical framework for model,
optimization assumptions, residual analysis and sampling for model validation are
described. Chapter 4 shows the results obtained by applying model to define
treatment rule for future patients. In this chapter the results of data restructuring,
regression analysis, residual diagnostic plots and regime value estimates can be
observed. Lastly, Chapter 5 describes the summary of the model and conclusions
from the model employment. Also, in this chapter the future work is listed so that
useful modifications and enhancement to the present model can be applied.
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CHAPTER 2
THEORY
2.1 Personalized Medicine
2.1.1 Definition and scope
Personalized Medicine is a medical term that highlights the methodical use
of individual patient’s information for optimizing that patient’s health. This
pharmacological paradigm is motivated by the fact that patients usually respond
differently to a treatment when primary outcome and side effects are compared among
a group of patients. The heterogeneity in treatment response among a group of patients
when a treatment is assigned to them has caused the ideological transition of researchers
from the notion of one-size-fits all to more logical method of personalized medicine.
Benefits of personalized medicine include improved compliance or adherence to
prescribed treatment which will result in enhanced patient care and reduces the overall
cost of healthcare. The phrase personalized medicine is not only popular in medical
community or among physicians but is also making its mark among many quantitative
researchers or statisticians. The reason behind this growth of interest is due to the
methodological challenges involved in constructing the treatment rules in personalized
medicine as they are evidence-based, and data driven. Thus, there is a broader scope
and unprecedented surge of interest among statisticians, engineers, computer scientists
and other quantitative researchers in this field of research which are leading to many
efficient methodological developments.
Dynamic treatment regimen, an important aspect of personalized medicine
defines a set of treatment rules at each treatment decision time and these treatment rules
are tailored to an individual patient according to the patient’s biomarkers, history,
characteristics and response to previous treatments. These decision rules prescribe the
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treatment the physician should follow or treatment decision she/he should take at each
decision points and the characteristics that influence the treatment decisions can be
demographics, case history, genetic information and other medical parameters of an
individual patient.
The concept of personalized medicine was described and appreciated in
medicine since 1960s and soon the publication followed on the Medline interface in
1999 [17]. Thus, tailoring treatments based on an individual patient’s biomarkers has
become a focus area for researchers in area of personalized medicine. Figure 2.1 shows
the evolution of personalized medicine from year 2000 to 2015 and various stages of
progress within these years [18]. From years 2000-2005 numerous projects were
undertaken for profiling personal genome with the aim providing personal genome
information to general public at a low cost. The era of personalized medicine began in
21st century medicine history which mainly focuses on pharmacogenetics, molecular
diagnostics and empirical treatments. Similarly, years 2005-2010 witnessed an
evolution in modern medicine by introduction of bioinformatics, genetic screening,
pharmacoproteomics and pharmacogenomics. Furthermore, years 2010-2015 have seen
substantial amount of development in field of personalized medicine as in these years
the concept of presymptomatic treatment, integrated healthcare, automated systems and
rational therapies came into practice.
Therefore, when integrating the pieces on a drawing board, the
evolutionary process of transfer from conventional medicine to personalized medicine
is inevitable and modern technologies in field of medicine has made medical
professionals who are trained in prebiotechnology era to retire and move towards use
of these newer technologies that involves genomic knowledge, molecular medicine,
pharmacogenetics and pharmacogenomics. Also, there is a need to bridge the gap
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between these two instances of medicine or in other words between conventional and
personalized medicine. For this purpose, Genomics and Personalized Medicine Act [19]
was passed in 2006 by the US government.

Figure 2.1. Evolution of Personalised medicine [18]

2.1.2 Medical Decision-Making Process
As mentioned in earlier chapters, the decision-making process is vital in
pharmacological practice as these decision rule is critical to the patient’s well-being in
long run. Although, decision makers try their best and take decisions as per their
experience for improvement in patient health, these decisions may not comply and may
provide altered results depending on the varying patient’s characteristics and
biomarkers. This is where personalized medicine comes in useful as the personalized
treatments march towards realizing a set of decision rules that governs the decisionmaking process or in other words informs a physician what to do in each decisionmaking stage where each decision solely depends upon the patient’s characteristics such
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as demographics, case history, genetic information, etc. For developing these decision
rules generally, the notions from decision theory such as utility are taken into
consideration and the decisions are undertaken based on these notion’s values.
Decision-theoretic approach have been taken into consideration since long
time in medical and health care decision-making. Parmigiani on 2002, asserted that the
decision theory ideas contribute in structuring and formally defining the goal and assists
in gathering, organizing and integrating the quantitative information that are required
for medical decision-making process [20]. Further, Parmigiani describes the Bayesian
approach for medical decision-making. However, here we consider different approach
and introduce single-stage and multi-stages decision problems in context of
personalized medicine and describe them mathematically.
2.1.2.1 Single-stage Decision
To understand the general idea of how decision theory, contributes to the
notion of personalized medicine, consider a single-stage decision problem where the
clinician should prescribe a single optimal treatment for an individual patient. When
this patient comes for a regular clinic visit the clinician will be able to observe certain
characteristics of the patient such as biomarker, results of some diagnostic test or results
from previous treatment. We consider these variables as history of the patient and
denote them by o, based on the values of o the decision-maker has to decide for example
whether to prescribe treatment a or a’. Thus, this setting is asking for a decision rule
which can be for example, “administer treatment a to the patient if his individual
characteristic o is lower than some threshold value, prescribe treatment a’ otherwise”.
Hence, decision rule is nothing but mapping of current state of patient that is described
by available information prior to treatment, into the space of possible treatment
decisions that a clinician can prescribe.
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The decision-making process involves statistical evaluation of the utility
of decision undertaken and the state at which this decision is made. The utility function,
u(o,a) describes the utility of prescribing treatment a at state o. Wald (1949), described
the foundations of general theory of statistical decision functions and derived that the
statistical decision problems can be expressed in form of opportunity loss (or regret)
function denoted as: 𝐿(𝑜, 𝑎) = 𝑠𝑢𝑝
⏟ 𝑢(0, 𝑎) − 𝑢(𝑜, 𝑎), where the supremum is taken
𝑎

over all possible treatment decisions at point a [21]. After describing the loss function
L(o,a) the goal now is to search for the treatment decision that minimizes this loss
function at state o and the decision that results in minimum loss function is equivalent
to optimal treatment decision. As the optimality of treatment decision depends upon the
state o which differ from one individual to other, thus this type of decision-making is
personalized. An alternative to loss function is formulating the problem directly in
terms of utility itself but the twist here is that the treatment decision which maximizes
the utility is chosen as optimal one for given state o. There are various ways for defining
utility function depending on the problem definition, one way is to assign it the
conditional expectation of primary outcome (Y) at the given state, i.e. 𝑢(𝑜, 𝑎) =
𝐸𝑎 (𝑌|𝑜). The expectation value is calculated according to the probability distribution
at treatment decision a.
Another method of describing optimal treatment is derived from different
econometrics and bio-medical literatures is known as welfare contrast [22-27]. The
welfare contrast gives the difference between the utilities of two different treatment
decisions, in our case, treatments a and a’. It is represented mathematically as,
𝑔(𝑜, 𝑎, 𝑎′ ) = 𝑢(𝑜, 𝑎) − 𝑢(𝑜, 𝑎′ ) where, 𝑔(𝑜, 𝑎, 𝑎′ ) gives the welfare contrast value and
𝑢(𝑜, 𝑎), 𝑢(𝑜, 𝑎′ ) are the utilities corresponding to treatment decisions a and a’,
respectively. In this case, we should note that a denotes the optimal decision so the
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value of 𝑔(𝑜, 𝑎, 𝑎′ ) is the regret of administering treatment decision a’. Thus, the
treatment that results in minimum regret value is considered as optimal treatment
decision at point o. The welfare contrast is also known as blip value in case of multistage decision problems which is described next [28].
2.1.2.2 Multi-stage Decision
As we move ahead from single-stage to multi-stage treatment decisions we
need to consider the effects of decisions made at each stage as the decision taken at one
stage can affect those made on later stages. Also, in multistage scenario instead of only
considering which treatment to choose among the treatment choices we need to be
conscious about which treatment to follow after a treatment is prescribed. In this
context, a Dynamic Treatment Regime (DTR) is administered to an individual patient
and can be described as a set of decision rules, where one treatment decision is made at
each intervention stage. These treatment rules adapt according to the state or
characteristics of patients which is time varying and depends on previous treatments or
patient’s history. For assigning decision rule at each stage the system takes the patient’s
individual characteristics such as biomarkers, response to previous treatments and other
demographics as input, and outputs the optimal recommended treatment for that
individual which may be drug dosage, timing of treatment, treatment type, etc. DTRs
are also known as treatment strategies [5, 29-31], adaptive treatment strategies [32, 33]
or treatment policy [34-36]and can be understood as the system that supports a decision
maker for making clinical or treatment decisions in medical scenario.
The next goal in multi-stage decision is the optimization of these DTR’s
that involves first definition of the optimization criteria and then use of some
optimization algorithm to obtain maximum utility. The optimization criteria are defined
by the maximization of utility functions which can be quantiles such as median or other
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characteristics of outcome distribution. The primary goals in this multi-stage decision
scenario can be listed as follows:
•

Comparison of utility between two or more treatment rules in every decisionmaking stage.

•

Optimization of DTR or identifying optimal treatment decision in each decision
stages by comparing utility values of each treatments and assigning the one
with maximum utility value as optimal.
Thus, the key in estimating optimal regimen is defining the utility

functions where the process is data-driven and an extension to single-stage decision
problems described earlier. To achieve these goals different utility functions were
considered in various literatures in past such as multiple stage-specific regret (loss)
functions [37], stage-specific blip functions (welfare contrasts) in structural nested
mean models framework [28]. Along with it other method known as Q-learning will
be implemented for further analysis in this thesis. Q-learning uses conditional
expectation of primary outcome or potential outcome as the utility function and the
potential outcome framework is discussed next.
2.1.3 Framework on Potential Outcomes
The potential outcome framework is used to quantify the result of
assigning a treatment in different stages of a dynamic treatment rule. Hence, comparing
this outcome value we will be able to estimate the utility values and build an optimized
decision rule. The framework was introduced by Neyman [38] for analyzing statistical
problems in agricultural experiments where time-dependent randomized trials were
considered. This presented framework was further extended by Rubin [39] and Robins
[40] in time-dependent randomized trials and observational data in the context of
dynamic treatment regimen. Thus, we can define potential outcomes as the set of all
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outcomes that is obtained when a treatment or a sequence of treatments is administered
to an individual patient.
Now, consider a two stage DTR setting where A1 denotes the treatment at
first stage and similarly A2 denotes that at second stage. Next, we need to consider the
baseline information which describes the characteristics of an individual before the
treatment at stage 1 is prescribed and it is denoted by X1. Further, X2 denotes the
additional information such as result of treatment at stage 1 and other biomarkers. Let
Y denote the final outcome after treatment at stage 2 is given and it is also our outcome
of interest. The observed data trajectory of an individual patient would be (X1, A1, X2,
A2, Y), where we can define potential outcome prior to second stage treatment as
X2*(a1), if treatment A1=a1 and that at end of second stage treatment as Y*(a1, a2) for
treatment sequence of A1=a1 and A2=a2.
Furthermore, in this framework of potential outcome following three
assumptions are important for estimating effects of dynamic treatment regimens:
•

Stable Unit Treatment Value Assumption (SUTVA) [40] states that there
should not be any disturbance in treatment between individuals or one patient’s
potential outcome should not be interfered by treatment allocated to another
patient. This assumption provides the stability or consistency in a way where
potential outcome will be equal to observed outcome or in other words it
maintains the connectivity between potential and observed outcomes. It can
also be expressed mathematically as X2*(a1) = X2 and Y*(a1, a2) = Y.

•

Next, the assumption of sequential ignorability which is also known as no
unmeasured confounding or conditional exchangeability) defines that,
depending upon the time-dependent covariates and treatment history up to time
tj, assigning treatment at stage Aj can be made independent of potential
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outcomes of the individual. If j= 1,2, and for regime (a1, a2), 𝐴1 ⊥
[𝑋2∗ (𝑎1 ), 𝑌 ∗ (𝑎1 , 𝑎2 )]|𝐻1 and 𝐴1 ⊥ 𝑌 ∗ (𝑎1 , 𝑎2 )|𝐻2 . The assumption always
holds for the process of sequential randomization which is usually performed
in the experimental setting of SMART design but must be evaluated according
to the problem or observational dataset in hand.
•

At last, we need to consider the assumption of positivity, which defines the
feasibility of a set of regimes for which treatment history with positive
probability of observation should also have positive probability of the
treatment results following the decision rule up to time tj with defined covariate
or treatment history. If this assumption is violated, we need to reconsider the
treatment regimens as violation of it will make us unable to estimate the effects
of DTRs.
Hence, the goal of DTR is to treat a patient with optimal treatment

depending upon the characteristics or evidence provided prior to treatment assignment.
The Bellman’s principle of optimality states that, “An optimal policy has the property
that whatever the initial state and initial decision are, the remaining decisions must
constitute an optimal policy with regard to the state resulting from the first
decision”[41]. Thus, we can use the theory of dynamic programming where by
knowing the functional distribution of the potential outcomes (e.g. X2*(a1) and Y*(a1,
a2)) we can estimate the optimal decision resulting maximum average outcome. For
implementation of above discussed processes and also making sure that all three
assumptions are not violated an experimental design is needed such as SMART which
is explained next [42].
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2.2 Sequential Multiple Assignment Randomized Trials (SMART) designs
2.2.1 Definition and applications
As observational data are usually high dimensional, and they also tend to
violate sequential ignorability assumption of DTR estimation we need to move towards
more practical and experimental setting. For this purpose, numerous literature on
clinical trial design employing experimental data are present [5, 29-32, 42, 43] that
defines construction of sequential multiple assignment randomized trial (SMART)
where a patient is randomized more than one time through all possible treatment options
at each stage and the treatment resulting maximum utility is selected as optimal
treatment that defines DTR. The SMART design offers randomization of treatment
options based on the individual patient’s biomarkers and clinical history. The design
also supports adaptive interventions which adapts to the system dynamics in a multistage trial through a sequence of decision rules that dictates the intervention path in
order to maximize long-term primary outcomes [6].
The main difference between Randomized Control Trial (RCT) and
SMART design is that the first one makes comparison between two or more treatments,
whereas the later compares the treatment regimens and constructs two or more decision
rules. The SMART design carries out the trial assignment process and within these
assigned trials the physician recognizes an optimal one, that maximizes the patients
well-being parameter is assigned to the patient. Hence, the SMART design enables an
agent to figure out the best treatment at some treatment stage or decision point, the
optimal treatment sequence depending upon response to previous treatments and
intermediate outcomes, best timing and modes of treatment delivery, and the process of
individualizing sequence of treatments according to biological, diagnostic and other
patient information.
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Generally, SMART design consists of two stage randomizations, where in
first stage patients are randomized to either of two or more treatments and it is followed
by periods of patients visit to clinic. The randomization process at second stage depends
upon response to previous treatment and patient characteristics over that time period.
So, in some SMART design programs a patient may or may not be randomized in the
second stage depending upon the response from first stage treatment. Thus, these
different types of randomization process differentiate one design from other and types
of SMART designs are discussed in next topic.
2.2.2 Types of SMART designs
There are commonly three ways in which SMART designs are constructed
and it can be more clearly shown in tree-diagram as in Figures 2.2, 2.3 and 2.4.
SMARTs with two stages and two or three treatment decisions per stage are the ideal
ones as the trial assignment in these kinds are more feasible and less time consuming.
However, designs like this can contain more than two stages and more than two or three
treatments for each stage. There is no compulsion that treatment in each stage should
be unique for example, in Figure 2.2, treatments C and D can be same as treatments G
and H, or E and F can be same as I and J. Similarly, it applies to SMART designs shown
in Figure 2.3 and 2.4. Further, the treatment options at first stage and that in second
stage can be same e.g., in Figure 2.2, treatments E or F can be same as treatment B and
I or J can be same as A.
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Figure 2.2. SMART design with two treatment options at each decision points where
both responders and non-responders are re-randomized to available treatment options
depending upon an individual’s status [42].
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Figure 2.3. SMART where only non-responders are re-randomized [42].
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Figure 2.4. SMART where re-randomization depends on both responder status and
initial treatment [42].
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All above figures represent different types of SMART designs where there
is distinction in process of re-randomization represented by letter R. Figure 2.2 shows
the design where all patients are re-randomized to available treatments depending upon
their response to previous treatments. This type of design was used for trial assignment
in alcohol dependency [44] who do not respond to Naltrexone, a placebo treatment for
alcoholics. If we observe this design closely we can find that there are eight ways of
assigning dynamic treatment regimens embedded within this design.
Similarly, Figure 2.3 shows most general type of SMART design where
re-randomization of treatments depends upon the response status of the target group.
Thus, in this type of design the responders are continued to a treatment without
randomization process whereas, only non-responders are randomized as our goal here
is to access best second-stage treatment option for these non-responding groups. These
kinds of design are mainly used for trial assignment in areas of ADHD [45], acute
myelogenous leukemia [46, 47], small-cell lung cancer [48], neuroblastoma [49, 50],
diffuse large cell lymphoma [51], multiple myeloma [52], and metastatic malignant
melanoma [53]. There are six embedded dynamic treatment regimes in this type of
SMART design.
Lastly, Figure 2.4 shows the next possible type of SMART design in which
the non-responders to a particular treatment that was assigned in first stage will only be
randomized in second stage of treatment decision. This type of design was used for trial
assignment in treatment for nonverbal children who were 5-8 years old with autism
spectrum disorders [54] under the project called the Adaptive CCNIA Developmental
and Augmented Intervention Study. Therefore, these are the main three types of
SMART design popular in medical literatures and implemented in trial assignment for
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personalized medicine. Further, in next topic we discuss about the design framework of
SMART for Sanford profile project.
2.2.3 Design Framework
As we are now familiar to different types of SMART designs and that they
are employed for trial assignment in estimation of optimal DTR. However, in Sanford
project the observational dataset is restructured according to SMART design as shown
in Figure 2.5, where, each subject or patient is randomized to treatment at each decision
points among the available treatment options.
Stage 2
Stage 1
Baseline
Same initial
treatment for
all patients

Switch

Switch
R

Augment

R

Switch
Augment

R
Augment

Figure 2.5. SMART design with two randomized stages and two treatment options at
each stage. Patients are randomized to treatments from left to right to one of the two
treatment options.
In the SMART design shown in Figure 2.5, first all the patients receive same
initial treatment called baseline treatment that can be any kind of standard care. Then,
after some time period the patients are driven forward to stage 1 in the design where
they are randomized to one of the two treatment categories namely “switch” or
“augment” current treatment. Again, after another period of time, patients in stage 1 are
re-randomized in stage 2 to again either of the two treatments, “switch” or ‘augment”,
the current treatment(s) from stage 1. Many different variations exist in designing of
SMART, for example, the number of treatments at each stage can be more than two and
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also there can be more than two stages. However, here we employ a two-stage SMART
with randomized binary treatments at each stage for dataset restructuring and making
this conducive for applying Q-learning, an optimization process for estimation of
optimal decision rule that will be discussed on later chapters. As the patients are
randomized to binary treatments these intervention options at each stage are coded
either -1 or 1. Thus, this type of adaptive intervention setting consists of four decision
rules embedded in total.
2.3 Reinforcement learning and Q-learning
2.3.1 History and Definition
Machine learning, a branch of artificial intelligence has become a popular
field of research for statisticians and data analyst over last few decades. The field of
machine learning that involves stochastic sequential decision process is referred to as
reinforcement learning (RL) in the realm of computer science. If we go back in history
then we will be aware that the term “reinforcement” was coined from learning behavior
of animals in experiments involving animal psychology where it points out the relation
between occurrence of event and the response, so there is greater probability that the
same response will occur again if the same situation is given. Let’s consider xt as state,
at as action and rt as reward from the action being taken in an environment where time
t is discrete then the process of reinforcement learning involves:
•

Trying a sequence of actions (at).

•

Recording the consequences or rewards (rt) of these actions.

•

Statistically estimating the relationship between actions (at) and their
consequences (rt).

•

Finally, selecting the action that produces most favorable consequence.
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Figure 2.6. Block diagram showing basic processes involved in reinforcement
learning.
Thus, as shown in Figure 2.6, reinforcement learning quantizes the
interaction between a learning agent and the environment it wants to learn about [55].
In this process, first an agent (physician) observes the status of states and put forward
or takes an action (treatment decision) from a set of possible actions. Then, the
environment (patient) responds to these actions by observing or outputting a reward
(patient’s well-being) and makes a transition to new state.
Additionally, from computer science perspective various complication or
computational issues may arise when there is an interaction between learning agent and
the environment it wants to learn from and in this case reinforcement learning is most
promising field to address these issues [55]. Although, most of the optimal control
theory and adaptive design requires some model that defines the physical state of the
system, reinforcement learning or more specifically Q-learning needs no such model as
it is a model-free method that can be used for obtaining personalized therapies. RL is
mainly popular in areas of machine learning, operations research, control theory and
game theory [56], however, there its popularity has grown also in statistical and
biomedical communities that uses RL for optimization of DTR’s [57].
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Dating back to history, first methods for solving multi-stage decision
problems are dynamic programming (DP) algorithms which was introduced by Bellman
in 1957 [41]. However, these classical DP techniques has some limitation while they
are implied in field of RL. These limitations can be summarized in two points: First,
these algorithms require a complete model of system dynamics which is we need to
have full knowledge of learning environment and multivariate distribution of data in
statistical terms. However, it is very complicated and impractical to have this
knowledge in areas of bio-medical and healthcare. Second, DP algorithms are proven
to be computationally expensive process and for high-dimensional medical data they
may face another problem called “curse of dimensionality”. Anyway, DP is important
in a sense that it gave the theoretical foundation for RL processes. Similarly, major
breakthrough occurred in the field of RL when Watkins on 1989 [58] introduced the Qlearning algorithm, which was implemented to solve multi-stage decision problems
depending upon the training data trajectories. Thus, Q-learning algorithm is able to
solve these issues of traditional DP algorithm and hence, it is also called approximate
dynamic programming algorithm.
In the field of health and medical studies, RL has used in treatment of
behavioral disorders where patients were administered multiple treatments in different
treatment stages [8]. Similarly, Q-learning was implemented for defining decision rules
in chronic psychiatric disorders [9] and also been successfully applied for segmenting
prostrate in transrectal ultrasound images [59]. Thus, summarizing on advantages of
RL we can say that this method does not rely on physical dynamics or accurate model
for describing time dependent optimal treatment strategies derived through clinical
training data. This feature, helps in applying heterogenic treatment across patient that
captures the notion of individualized therapies. Next, the process of RL focuses on long-
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term benefits of a treatment decision rule to an individual by considering response of
previous treatment, patient’s history and also delayed effects of treatment assigned.
2.3.2 Mathematical Definition
In clinical scenario, reinforcement learning involves trying a sequence of
treatment actions, recording the results of these treatments and statistically estimating
the relations between these treatments and their results. The treatments assigned to the
patient interacts with them and known as the “environment” which may be human body,
DNA or proteomics etc. These interactions happen continuously during trial assignment
and thus, the environment interacts with the actions and provides the feedback as
potential outcomes. Mathematically, let’s denote the environment (states) and possible
actions (“treatments”) as X and A, respectively. Both of these variables are random and
̅̅̅𝑡 = {𝑋1 , 𝑋2 , … , 𝑋𝑡 }. and similarly, define actions as ̅̅̅
time-dependent thus, 𝑋
𝐴𝑡 =
{𝐴1 , 𝐴2 , … , 𝐴𝑡 }. When the values of random variables X and A are realized, we denote
them in lower case as 𝑥̅𝑡 = {𝑥1 , 𝑥2 , … , 𝑥𝑡 } and 𝑎̅𝑡 = {𝑎1 , 𝑎2 , … 𝑎𝑡 }. Assume P as
distribution of above finite longitudinal trajectories when sampled. The distribution of
̅̅̅̅̅̅
̅̅̅̅̅̅
each present state Xt is conditional on previous state values of (𝑋
𝑡−1 , 𝐴𝑡−1 ). Let’s
denote these conditional densities as {𝑓1 , … , 𝑓𝑇 } and again the expected values for each
distributions P is denoted as E.
As patients are given a treatment at in time t, after each of these time steps
of t they receive a numerical reward say rt which represents patient’s status or wellbeing after that treatment. Mathematically, the reward function is depended upon:
previous state 𝑥̅𝑡 , action 𝑎̅𝑡 , and current state xt+1, where t= 0, 1, …, T and represented
as:
𝑟𝑡 = 𝑅(𝑥̅𝑡 , 𝑎̅𝑡 , 𝑥𝑡+1 )

(2.1)
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In RL however, to learn what to do when similar events happen in future,
first we need to map situations from state space X to actions to be taken from action
space A, depending on the goal which may either be to maximize or minimize the
expected value of discounted return:
𝑇
2

𝑇

𝑅𝑡 = 𝑟𝑡 + 𝛾𝑟𝑡+1 + 𝛾 𝑟𝑡+2 + ⋯ + 𝛾 𝑟𝑡+𝑇 = ∑ 𝛾 𝑘 𝑟𝑡+𝑘

(2.2)

𝑘=0

In equation (2.2), 𝛾 denotes the discount rate whose values ranges from 0 ≤ 𝛾 ≤ 1,
which means that the future rewards are discounted geometrically depending on the
value of 𝛾. The different values of discount rate affect whether the future rewards are
taken into consideration or not. For example, if 𝛾 = 0, then in the same equation (2.2)
we can observe that 𝑅𝑡 = 𝑟𝑡 , which means only immediate reward is considered,
whereas, when 𝛾 = 1 the future rewards are strongly taken into account and under these
circumstances the reward function are either maximized or minimized over the long
run.
The next important factor of RL algorithm is an exploration “policy” or
treatment policy in medical terms. The policy is represented as p and defined as the
mapping of state 𝑥̅𝑡 and action 𝑎
̅̅̅̅̅̅
̅𝑡 , 𝑎
̅̅̅̅̅̅),
𝑡−1 to the probability 𝑝𝑡 (𝑎| 𝑥
𝑡−1 which is the
probability of action a being taken when given history is (𝑥̅𝑡 , 𝑎
̅̅̅̅̅̅).
𝑡−1 It can be described
in other way as the sequence of decision rules for e.g. {𝑑1 , … , 𝑑 𝑇 } and it can also be
considered as an action i.e. {𝑑1 , … , 𝑑 𝑇 } = 𝑎𝑡 in a nonstationary, non-Markovian but
deterministic system. In the training data, if its distribution is denoted by Pd then the
expectations with respect to these distributions can be denoted as Ed. The goal of RL
study is to find out the treatment that results in maximum reward for the patient or in
other words seek for the policy that yields maximum value of expectations with respect
to sum of rewards over time.
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Another key estimation in RL system is the estimation of value function,
which is defined as state or state-action pair function that combines the total reward an
agent can gather, considering all expected future reward when starting from a given
state. Suppose, D is the set consisting of all policies such that 𝑑 ∈ 𝐷 then the value
function denoted by V(x) is defined as the sum of expected rewards with initial state x
and following the policy 𝑑 ∈ 𝐷. Mathematically, value function is denoted as:
𝑉(𝑥) = 𝐸𝑑 [𝑅𝑡 |𝑥𝑡 = 𝑥] = 𝐸𝑑 [∑𝑇𝑘=1 𝛾 𝑘 𝑟𝑡+𝑘 |𝑥𝑡 = 𝑥]

(2.3)

As the state or state-action pairs are time-dependent, value function for a history set
(𝑥̅𝑡 , 𝑎
̅̅̅̅̅̅)
𝑡−1 is given by:
𝑇
𝑘
̅̅̅ ̅𝑡 , ̅̅̅̅̅̅
𝑉𝑡 (𝑥̅𝑡 , 𝑎
̅̅̅̅̅̅)
𝐴𝑡−1 = 𝑎
̅̅̅̅̅̅]
𝑡−1 = 𝐸𝑑 [∑ 𝛾 𝑟𝑡+𝑘 | 𝑋𝑡 = 𝑥
𝑡−1

(2.4)

𝑘=1

The main difference between equations (2.3) and (2.4) is the function pair they define,
as equation (2.3) defines the state-value functions of policy d whereas equation (2.4)
defines action-value function for policy d [57].
Now, next goal is to estimate the best policy that would maximize the final
reward in the long run. Thus, optimal value function can be defined as:
𝑉𝑡𝑜𝑝𝑡 (𝑥̅𝑡 , ̅̅̅̅̅̅)
𝑎𝑡−1 = 𝑚𝑎𝑥𝑑𝜖𝐷 𝑉𝑡 (𝑥̅𝑡 , 𝑎
̅̅̅̅̅̅)
𝑡−1
𝑇

̅̅̅𝑡 = 𝑥̅𝑡 , ̅̅̅̅̅̅
= 𝑚𝑎𝑥𝑑𝜖𝐷 𝐸𝑑 [∑ 𝛾 𝑘 𝑟𝑡+𝑘 | 𝑋
𝐴𝑡−1 = 𝑎
̅̅̅̅̅̅]
𝑡−1

(2.5)

𝑘=0

On the basis of equation (2.5), we can define an optimal policy as the
policy that results in maximum value of value function 𝑉𝑡 (𝑥̅𝑡 , ̅̅̅̅̅̅).
𝑎𝑡−1 The optimal policy
is denoted as dopt and if this policy exists we can further establish the Bellman optimality
equation for this optimal policy. The Bellman optimality equation gives the relationship

31
between values of the current state and its successor states and it shows the fact that
optimal policy yields the best expected result or is the best action with respect to current
state. The Bellman optimality equation for 𝑉𝑡𝑜𝑝𝑡 (𝑥̅𝑡 , 𝑎
̅̅̅̅̅̅)
𝑡−1 can be derived as follows:
∞
𝑘
̅̅̅̅̅̅
̅̅̅ ̅𝑡 , 𝐴
𝑉𝑡𝑜𝑝𝑡 (𝑥̅𝑡 , 𝑎
̅̅̅̅̅̅)
̅̅̅̅̅̅]
𝑡−1 = 𝑚𝑎𝑥𝑎𝑡 𝐸𝑑𝑜𝑝𝑡 [∑𝑘=0 𝛾 𝑟𝑡+𝑘 | 𝑋𝑡 = 𝑥
𝑡−1 = 𝑎
𝑡−1
𝑘
̅̅̅ ̅𝑡 , ̅̅̅̅̅̅
= 𝑚𝑎𝑥𝑎𝑡 𝐸𝑑𝑜𝑝𝑡 [𝑟𝑡 + 𝛾 ∑∞
𝐴𝑡−1 = 𝑎
̅̅̅̅̅̅]
𝑡−1
𝑘=0 𝛾 𝑟𝑡+𝑘+1 | 𝑋𝑡 = 𝑥
𝑜𝑝𝑡 ̅̅̅̅̅̅ ̅̅̅ ̅̅̅
̅̅̅̅̅̅
(𝑋𝑡+1 , 𝐴𝑡 )|𝑋𝑡 = 𝑥̅𝑡 , 𝐴
= 𝑚𝑎𝑥𝑎𝑡 𝐸[𝑟𝑡 + 𝛾𝑉𝑡+1
̅𝑡 ]
𝑡−1 = 𝑎
𝑜𝑝𝑡 ′
𝑎
𝑎
= 𝑚𝑎𝑥𝑎𝑡 ∑𝑥 ′ 𝑃𝑥𝑥
′ [𝑅𝑥𝑥 ′ + 𝛾𝑉𝑡+1 (𝑥 )]

(2.6)

Where,
𝑎
′
𝑃𝑥𝑥
̅̅̅̅̅̅
̅𝑡 = 𝑥, 𝑎̅𝑡 = 𝑎}
′ = Pr{𝑥
𝑡+1 = 𝑥 |𝑥
𝑎
𝑅𝑥𝑥
̅𝑡 = 𝑥, 𝑎̅𝑡 = 𝑎𝑥𝑡+1 = 𝑥 ′ ]
′ = 𝐸[𝑟𝑡 |𝑥

(2.7)

(2.8)

Equations (2.7) and (2.8) denotes two forms of Bellman equations for
𝑜𝑝𝑡
𝑉𝑡𝑜𝑝𝑡 (𝑥̅𝑡 , 𝑎
̅̅̅̅̅̅).
, it must satisfy:
𝑡−1 Also, for a policy to be optimal i.e.𝑑
𝑜𝑝𝑡 ̅̅̅̅̅̅ ̅̅̅ ̅̅̅
(𝑋𝑡+1 , 𝐴𝑡 )|𝑋𝑡 = 𝑥̅𝑡 , ̅̅̅̅̅̅
𝑑𝑡𝑜𝑝𝑡 (𝑥̅𝑡 , 𝑎
̅̅̅̅̅̅)𝜖
arg 𝑚𝑎𝑥𝑎𝑡 𝐸[𝑟𝑡 + 𝛾𝑉𝑡+1
𝐴𝑡−1 = 𝑎̅𝑡 ]
𝑡−1

(2.9)

Thus, above mathematical definition of Reinforcement Learning technique
depicts that observing reward of present state and transition to next state does not
require knowledge for model of the environment. Both of these processes are
determined by the consequences of interaction between environment and the actions
taken. This aspect of RL differentiates it from other form of Dynamic Programming.
2.3.3 Q-function Estimation
Q-learning is a reinforcement learning technique which targets on
estimating and maximizing the above discussed value function, rather than minimizing
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regret or any other blip function. The blip function is the concept fundamental to DTR
estimation and is also known as contrast function which is defined as the difference
between expected outcome of a patient under two different treatments [60]. The value
functions are also called Q-functions in Q-learning scenario. So, to estimate these Qfunctions we should first consider the dimension of state variables in state-space (X)
and treatment actions in action-space (A). In order to obtain the estimated values of
these Q-functions various approaches such as linear least square regression, Support
vector machines regressions, extremely randomized trees, etc. are implemented.
However, it has been observed that estimation of these functions is mainly the
approximation of least squares value iteration [61-63].
For estimating Q-function, first we need to define an error parameter (𝜃𝑡 )
for the tth Q-function and this parameter should satisfy:
2
̅̅̅
̅̅̅̅̅̅
̅̅̅ ̅̅̅
𝜃𝑡 𝜖 arg 𝑚𝑖𝑛𝜃 𝐸𝑛 [𝑟𝑡 + 𝑚𝑎𝑥𝑎𝑡+1 𝑄𝑡+1 (𝑋
(2.10)
𝑡+1 , 𝐴𝑡 , 𝑎𝑡+1 ; 𝜃𝑡+1 ) − 𝑄𝑡 (𝑋𝑡 , 𝐴𝑡 ; 𝜃)]

Q-learning is a regression-based approximate dynamic programming algorithm that
depends on Q-functions where, input to the system are the training data and output is
the function approximation for estimating potential final outcome. The SMART design
assists in providing the training data as it consists of trial assignment or treatment
decision for an individual at different time interval. The number of Q-functions to be
estimated depends upon the number of stages in SMART design. Therefore, for a twostage SMART, we should follow a bottom to top (backwards) approach, i.e. initially
second stage Q-function should be approximated then we should move on to do that for
first stage. Further, if we consider two treatment options available at each treatment
stages then we need to code these treatment options as 1 and 0. Suppose, A1 gives the
treatment decision at stage 1 and A2 gives that at stage 2, then based on the training
data, the regression model at stage 2 or Q2 can be defined as:
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𝑄2 (𝑋, 𝐴2 ; 𝜃) = 𝛽0 + 𝛽1 𝑋 + (𝛽2 + 𝛽3 𝑋)𝐴2

(2.11)

Where, 𝜃 = (𝛽0 , 𝛽1 , 𝛽2 , 𝛽3 ) are the values of regression coefficient or intercept values
and X gives the values of states indicating the response of treatment or summary of side
effects up to the end of first decision point. For low dimensional action space, it is
conducive to implement multiple regression models for function approximation
however, as the dimension increases it becomes necessary to move towards quadratic
or higher order regression analysis.
2.4 Probabilistic Framework
The number of stages in a RL problem, where in stage there is interaction
between the agent and the environment can be of finite or infinite numbers. However,
the infinite-horizon problem is beyond the scope of this thesis. So, let’s consider a RL
problem with finite number of stages say K and let j be one of the stages within K where,
1 ≤ 𝑗 ≤ 𝐾. Thus, at stage j suppose the agent observes a state Oj which may belong to
a vector consisting of discrete or continuous variables and to have further interaction to
the environment the agent then executes an action Aj which should belong to a vector
of discrete variables. The interaction between agent and the environment through the
executed action results in a real-valued reward say Yj. After, this interaction the agent
moves on to the next stage. Here, as the problem is of finite- horizon we can define
𝑂̅𝑗 = (𝑂1 , … , 𝑂𝑗 ) and 𝐴𝑗̅ = (𝐴1 , … , 𝐴𝑗 ). Now, the history set Hj can be defined as the
̅ ) at stage
vector of all the covariates information consisting the elements say (𝑂̅𝑗 , 𝐴𝑗−1
j. Then, the reward can be denoted as the function of history set Hj, the current action
executed Aj and the transition to next state Oj+1 i.e.
𝑌𝑗 = 𝑌𝑗 (𝐻𝑗 , 𝐴𝑗 , 𝑂𝑗+1 ) = 𝑌𝑗 (𝑂̅𝑗, 𝐴𝑗̅ , 𝑂𝑗+1 )

(2.12)
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In statistical term, the reward is considered like potential outcome and in some cases,
there can be only one ultimate reward with all previous rewards assumed to be 0.
Now, let’s define a policy d as a vector of all the decision rules and are
determined through mapping from history space (Hj) to the action space (Aj) i.e.
𝑑𝑗 : 𝐻𝑗 → 𝐴𝑗 , for 1 ≤ 𝑗 ≤ 𝐾. For a stochastic process the policy defines the mapping of
the history space to the space of probability distributions of the action space and is
denoted as 𝑑𝑗 (𝑎𝑗 |ℎ𝑗 ). Also, the policy space can be defined as the function space of
collection of these policies that are mapped between history and Action space, this
function space is denoted as D.
Furthermore, let’s consider a finite-horizon trajectory of training data set as
{𝑂1 , 𝐴1 , 𝑂2 , … , 𝐴𝐾 , 𝑂𝐾+1 }. The training dataset consists of the records for n number of
individuals, so, we will have n number of these trajectories. If the subjects are sampled
randomly following some fixed probability distribution say 𝑃𝜋 . However, the
probability distributions of each Oj that are conditional on (Hj-1, Aj-1) are unknown thus,
suppose these conditional densities as {𝑓1 , … , 𝑓𝐾 } and corresponding policies as 𝜋 =
(𝜋1 , … , 𝜋𝐾 ), then depending on history Hj the probability that action aj is taken is given
by 𝜋𝑗 (𝑎𝑗 |𝐻𝑗 ). We consider that all the actions have positive probability of being
executed. Then, the likelihood of trajectory {𝑜1 , 𝑎1 , 𝑜2 , … , 𝑎𝐾 , 𝑜𝐾+1 } under the
probability distribution 𝑃𝜋 is given by:
𝐾

𝑓1 (𝑜1 )𝜋1 (𝑎1 |𝑜1 ) ∏ 𝑓𝑗 (𝑜𝑗 |ℎ𝑗−1 , 𝑎𝑗−1 )𝜋𝑗 (𝑎𝑗 |ℎ𝑗 )𝑓𝐾+1 (𝑜𝐾+1 |ℎ𝐾 , 𝑎𝐾 )

(2.13)

𝑗=2

Now, we denote the expectation value of the policy with respect to distribution 𝑃𝜋 as
𝐸𝜋 . Again, let’s denote the distribution of an arbitrary policy 𝑑 = (𝑑1 , … , 𝑑𝐾 ) as 𝑃𝑑 and
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this policy is also responsible for action generation. So, d is the deterministic policy and
the likelihood of trajectory {𝑜1 , 𝑎1 , 𝑜2 , … , 𝑎𝐾 , 𝑜𝐾+1 } under distribution 𝑃𝑑 is given by:
𝐾

𝑓1 (𝑜1 )𝕀[𝑎1 = 𝑑1 (𝑜1 )] ∏ 𝑓𝑗 (𝑜𝑗 |ℎ𝑗−1 , 𝑎𝑗−1 )𝕀[𝑎𝑗 = 𝑑𝑗 (ℎ𝑗 )]𝑓𝐾+1 (𝑜𝐾+1 |ℎ𝐾 , 𝑎𝐾 )

(2.14)

𝑗=2

Also, if we consider the policy d as a stochastic process then the likelihood becomes:
𝐾

𝑓1 (𝑜1 )𝑑1 (𝑎1 |𝑜1 ) ∏ 𝑓𝑗 (𝑜𝑗 |ℎ𝑗−1 , 𝑎𝑗−1)𝑑𝑗 (𝑎𝑗 |ℎ𝑗 )𝑓𝐾+1 (𝑜𝐾+1 |ℎ𝐾 , 𝑎𝐾 )

(2.15)

𝑗=2

The expectation with respect to the distribution Pd is denoted by Ed. Then, the goal of
statistical RL is to learn an optimal policy say d* that has the greatest possible expected
value within that class.
The value function can be defined as total expected future reward from a
particular starting state and then after choosing actions according to some policy. Thus,
at state o1 with respect to an arbitrary policy d we can denote the value function as
follows:
𝐾

𝑉 𝑑 (𝑜1 ) = 𝐸𝑑 [∑ 𝑌𝑗 (𝐻𝑗 , 𝐴𝑗 , 𝑂𝑗+1 )|𝑂1 = 𝑜1 ]

(2.16)

𝑗=1

When considered j stages, the value function for history hj is the total expected rewards
from stage j (1 ≤ 𝑗 ≤ 𝐾)onwards and is denoted as:
𝐾

𝑉𝑗𝑑 (ℎ𝑗 ) = 𝐸𝑑 [∑ 𝑌𝑘 (𝐻𝑘 , 𝐴𝑘 , 𝑂𝑘+1 )|𝐻𝑗 = ℎ𝑗 ]

(2.17)

𝑘=𝑗

𝑑 (∙)
Then, we set 𝑉𝐾+1
= 0 and by definition we know 𝑉1𝑑 (⋅) = 𝑉 𝑑 (⋅), the value

functions can be now recursively expressed as:
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𝐾

𝑉𝑗𝑑 (ℎ𝑗 ) = 𝐸𝑑 [∑ 𝑌𝑘 (𝐻𝑘 , 𝐴𝑘 , 𝑂𝑘+1 )|𝐻𝑗 = ℎ𝑗 ]

(2.18)

𝑘=𝑗

𝐾

= 𝐸𝑑 [𝑌𝑗 (𝐻𝑗 , 𝐴𝑗 , 𝑂𝑗+1 )|𝐻𝑗 = ℎ𝑗 ] + 𝐸𝑑 [ ∑ 𝑌𝑘 (𝐻𝑘 , 𝐴𝑘 , 𝑂𝑘+1 )|𝐻𝑗 = ℎ𝑗 ]
𝑘=𝑗+1

𝐾

= 𝐸𝑑 [𝑌𝑗 (𝐻𝑗 , 𝐴𝑗 , 𝑂𝑗+1 )|𝐻𝑗 = ℎ𝑗 ] + 𝐸𝑑 [𝐸𝑑 [ ∑ 𝑌𝑘 (𝐻𝑘 , 𝐴𝑘 , 𝑂𝑘+1 )|𝐻𝑗+1 ]|𝐻𝑗 = ℎ𝑗 ]
𝑘=𝑗+1

𝑑
= 𝐸𝑑 [𝑌𝑗 (𝐻𝑗 , 𝐴𝑗 , 𝑂𝑗+1 )|𝐻𝑗 = ℎ𝑗 ] + 𝐸𝑑 [𝑉𝑗+1
(𝐻𝑗+1 )|𝐻𝑗 = ℎ𝑗 ]

𝑑
= 𝐸𝑑 [𝑌𝑗 (𝐻𝑗 , 𝐴𝑗 , 𝑂𝑗+1 ) + 𝑉𝑗+1
(𝐻𝑗+1 )|𝐻𝑗 = ℎ𝑗 ], 1 ≤ 𝑗 ≤ 𝐾

Finally, the optimal treatment strategy can be defined under the value function as:
𝑉𝑗𝑜𝑝𝑡 (ℎ𝑗 ) = 𝑚𝑎𝑥𝑑∈𝐷 𝑉𝑗𝑑 (ℎ𝑗 )

(2.19)

The optimal value functions also satisfy the Bellman equation as:
𝑜𝑝𝑡

𝑉𝑗

𝑜𝑝𝑡

(ℎ𝑗 ) = 𝑚𝑎𝑥𝑎𝑗 ∈𝐴𝑗 𝐸[𝑌𝑗 (𝐻𝑗 , 𝐴𝑗 , 𝑂𝑗+1 ) + 𝑉𝑗+1 (𝐻𝑗+1 )|𝐻𝑗 = ℎ𝑗 , 𝐴𝑗 = 𝑎𝑗 ]

(2.20)

Also, the value of policy d denoted as Vd is given by taking the average value or
marginal mean outcome over all possible initial observation and can be expressed as:
𝐾
𝑑

𝑉 =

𝐸𝑂1 [𝑉 𝑑 (𝑂1 )]

= 𝐸𝑑 [∑ 𝑌𝑘 (𝐻𝑘 , 𝐴𝑘 , 𝑂𝑘+1 )]

(2.21)

𝑘=1

The probabilistic framework discussed above considers a classical RL approach
where optimal rule is chosen as the one that maximizes the value function. However,
we can consider Q-function that are nothing but action-value functions where “Q”
stands for quality of actions and can be considered as a substitute to Vd. Thus, the Qfunction at stage j considering the policy as d can be defined as the total expected future
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reward starting from history set hj and undergoing actions aj according to the policy d.
Mathematically,
𝑑
𝑄𝑗𝑑 (ℎ𝑗 , 𝑎𝑗 ) = 𝐸[𝑌𝑗 (𝐻𝑗 , 𝐴𝑗 , 𝑂𝑗+1 ) + 𝑉𝑗+1
(𝐻𝑗+1 )|𝐻𝑗 = ℎ𝑗 , 𝐴𝑗 = 𝑎𝑗 ]

(2.22)

Also, the optimal Q-function at stage j can be expressed as:
𝑜𝑝𝑡
𝑄𝑗𝑜𝑝𝑡 (ℎ𝑗 , 𝑎𝑗 ) = 𝐸[𝑌𝑗 (𝐻𝑗 , 𝐴𝑗 , 𝑂𝑗+1 ) + 𝑉𝑗+1
(𝐻𝑗+1 )|𝐻𝑗 = ℎ𝑗 , 𝐴𝑗 = 𝑎𝑗 ]

(2.23)

Therefore, in medical decision-making scenario it is a subject of extreme
interest in estimating the value of 𝑄𝑗𝑜𝑝𝑡 , which can directly estimate the optimal policy
and enables an agent for choosing an optimal treatment decision.
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CHAPTER 3
METHODOLOGY
3.1 Training Data Acquisition
The training data are the clinical trials from Sanford profile health and they
consist of body weight of patients over multiple time points, resulting in a dataset which
consists of trajectories with patient baseline weight, weight after 4 months and final
weight after 12 months. There are two treatment decision points at 4 months and 12
months period and the dataset also consists of other patient characteristics such as
gender, age, race, etc. Although there are various possible ways for data collection
Clinical trials can be taken as very reliable source in case of applying reinforcement
learning approaches. Also, the block diagram for visualizing the process or
methodology used in this thesis for obtaining optimal DTR can be shown as:

Acquire the
training data

Future patients’
prognostic and
predictive covariates

Fit the model to training data using
regression analysis for employing
optimization procedures

Mathematical
Model

Estimated Optimal
treatment decision
rule

Figure 3.1. Block Diagram showing the process of building a Mathematical Model for
estimating optimal DTR.
For deriving the data using clinical trials design, “Sequential Multiple
Assignment Randomized Trial” (SMART) design method is very promising as
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suggested by various studies [8, 31, 64]. This type of trial design method pairs the
treatment decisions or in RL term, actions to their corresponding results or clinical
outcomes (states). There are multiple stages where an agent or clinician should make
treatment decisions, at each stage one treatment is randomly assigned with probability
0.5 to participants then the result is observed. So, an individual is randomized through
different treatment plans which enables a decision-maker to observe the final outcomes
considering all possible treatment patterns. For example, if we consider a trial with
three stages namely pre-treatment (S0), mid-treatment (S1) and post-treatment (S2) and
two treatment decisions at each stage that are actions a1 and a2. Then, for pre-treatment
stage we may randomly choose one treatment decision for some patients and another
treatment for some others and evaluate the initial results observed from these
treatments. After the first treatment stage in design we further randomize treatments
(a1, a2) for patients to observe the treatment outcomes under these stages. At last, we
would have then assigned all possible four patterns of treatment assignment randomly
to a group of patients and observed their outcomes. Hence, after we have performed
this trial assignment we can observe a training dataset which can be further used to
define an optimal treatment decision for an individual and it will be discussed later in
this chapter.
As discussed earlier the design of this thesis focuses on weight management
treatment plan for patients enrolled in Sanford Profile Health. Therefore, the important
goal here is to prescribe an optimal weight management treatment plans for an
individual with certain attributes and prove that this treatment plans will work best for
her/him depending upon her/his characteristics. In this scenario, for obtaining the
training data the restructuring of Sanford Health Data according to SMART design is
the preliminary task for data acquisition. Thus, the dataset consists of baseline_weight,
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month4_weight and month12_weight which are patients’ pre-treatment weight, midtreatment weight and post-treatment weight respectively. The dataset also consists of
the information about treatment assigned at stages A1 and A2, which are the midtreatment and post-treatment decisions respectively. As, there are two treatment options
are each stage these two treatments are coded as 1 and -1. Various patient’s attributes
such as gender, race, heights are also available in the dataset.
3.2 Model Definition
3.2.1 Mathematical Framework
3.2.1.1 State and Action Modelling
In many medical settings representing state space is very important for
defining a mathematical model as general medical outcome are mixed values of discrete
categorical and continuous variables. The state space in medical scenario are typically
of high dimension and this may pose several difficulties in state space representation
such as:
•

State that can define sufficient statistic for the problem.

•

Effect in modelling due to irrelevant state variables.

•

Curse of dimensionality due to high dimensional spaces.

•

Need of defining appropriate state variables.
A state model can be defined as one having sufficient statistic in a

statistical sense if it can specify the relevant parameters, completely of the associated
distributions with the help of comprehensive information that it should contain [65].
Further, as we are considering the context of RL, a state representation should be able
to sufficiently specify the distribution of future rewards and state transitions. Also in
RL, policy d is the mapping from state to action space, therefore if the state lacks the
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sufficient information about the associated distributions then the policy also may lack
quality. In Medical terms, it is very complicated to know the sufficient quantity or
quality of state variables so more or less we have to rely on our intuition for selecting
appropriate state variables.
Therefore, we need to be careful in including those state variables that are
relevant in defining the overall statistic of the model and avoiding source of errors and
data inefficiency. In RL problems as the number of state variables grows, the system
tends to be affected by “curse of dimensionality”, which explains that the number of
states increase exponentially with respect to number of dimensions in the system. The
effect of this curse can also be observed while increasing the number of data to obtain
a particular confidence boundary [65]. Discretizing the state variable may seem
effective in tackling these drawbacks, however, it should be performed very carefully,
which requires complete knowledge of specific limitations in behavior of relevant state
variables. In some cases, the discretization method may not be very complicated as for
e.g. mapping of blood pressure into hypotension, prehypertension, etc., on other hand,
in many cases this type of categorization may not be straightforward which can
introduce bias in value function estimation. Thus, in that case, methods such as
function approximation and other regularization techniques are robust and are
important in reducing the effect of dimensionality and overall presence of irrelevant
state variables in the system, so, these methods are of great help when such obstacles
are encountered [66].
The mathematical model for Sanford Profile defines five state variables
namely, gender, race, parent_BMI, baseline_BMI and month4_BMI where gender and
race gives the respective information about an individual coded as 0 and 1. Similarly,
parent_BMI defines the averaged Body Mass Index (BMI) of patient’s parents and
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baseline_BMI, month4_BMI are the pre-treatment and mid-treatment BMI values of
the patient. There are also two treatment decision points and two treatment options
coded as 1 and -1 at each of these decision points.
After defining the state space next, we need to define the set of action space
or treatment interventions to be precise. The set of actions may change as we move
from one stage of randomization to another in a SMART trial design. Generally,
majority of DTRs consists of small and discrete set of actions for e.g. Treatment 1 vs.
Treatment 2. However, we may consider some cases where the action space is
continuous which is beyond the scope of this thesis. Action space being continuous
also poses numerous problems in trial design and further optimization of DTR. As we
know that RL problem tries to optimize the DTR setting by maximizing the outcome
over action space after each iteration. Therefore, maximizing outcome over continuous
action space can introduce bias in learning as it requires numerical approximation. In
addition to that, the RL algorithm randomizes all possible treatment or actions and
selects the one with maximum reward, so, exploring or randomizing in continuous
space is numerically infeasible. Thus, discrete action space with few dimensions
generally results in rapid and confident attainment of RL solutions.
In our case, there are two treatment actions available at each stage in the
SMART design. The decisions are denoted as A1 and A2 in the first stage and second
stage decision respectively of the model and the treatments are coded -1 and 1 defining
two different types of actions in an action space.
3.2.1.2 Time Horizon
After defining state and action spaces we need to define the time limit or
choose the time horizon for the mapping between these spaces to continue in the system.
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In RL problem the time horizon can be categorized into either “finite” or “infinite”
cases. In case of finite time horizon, the problem of decision making terminates after
some finite number of time period or steps. In most of the cases the number of time
steps or at least the upper bound of time period are known in advance to the agent. Any
kind of medical therapy that aims in moving patients from “bad” to “good” state can be
thought of as a finite time horizon as in these cases the goal is to cure a disease or be at
remission.
Alternatively, in case of treatments with short time steps and those with
chronic conditions it is beneficial to assume an infinite time horizon of treatment
decisions. The RL problem in this scenario should be able to operate and provide
decision rules indefinitely. An example for infinite time horizon case can be one where
response to treatment of a patient may be unstable and due to this a continual treatment
is required, otherwise the patient condition may deteriorate and may end up in state of
relapse.
In our case as the stages of treatment are not infinite and there are two
possible treatment options at each stage thus, it is a finite horizon problem with definite
number of time steps. As the problem statement of the research suggests estimating the
optimal treatment decision rule for patients’ weight management, the treatments
decision made should work in patients’ well-being and after the state of well-being or
weight management is obtained these treatments are not continued, however, regular
exercise and balanced diet are essential for sustaining the lost weight.
3.2.1.3 Reward Function
In RL problem, the result of mapping between state and action space is
eventually depicted upon the reward function, from which an agent can estimate the
cost or utility of employing an action at some stage of clinical trial. The reward function
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can be linear, nonlinear or discontinuous, however, only requirement is that it should
bounded by entire state and action space. Studies also show that the choice of reward
function effects the learning rates in RL algorithms [67, 68].
An efficient reward function should always clearly reflect the desired goal
and can only be a simple function for e.g. in game playing an agent can define a reward
function as it wins or loses the game [69, 70]. Mathematically, the reward function in
this case can be simply defined as:
1 𝑎g𝑒𝑛𝑡 𝑤𝑖𝑛𝑠 𝑡ℎ𝑒 𝑔𝑎𝑚𝑒 𝑎𝑡 𝑠𝑡𝑎𝑡𝑒 𝑠,
𝑅(𝑠, 𝑎) = {
0
𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒.

(3.1)

Above equation shows a simple reward function where choosing a reward is based upon
whether an agent wins or loses the game. The agent is rewarded 1 if it wins whereas it
is awarded 0 otherwise.
Similarly, reward function in medical setting should define the tradeoffs
between the costs of treatments and costs of symptoms. For instance, in HIV model
[71] following reward function was considered:
𝑅(𝑠, 𝑎) = 𝑐1 𝑎12 + 𝑐2 𝑎22 + 𝑐3 𝑠𝑉 + 𝑐4 𝑠𝐸

(3.2)

In above equation (3.2), a1 and a2 are the real-valued actions that represents the drug
dosage levels similarly, sV and sE are the state variables that denotes viral load and
immune response, respectively. Also, the coefficients c1 to c4 are constants whose
values should define the priorities of the agent and should narrow the differences in
range between state and action spaces. In this scenario, it is favorable to an agent in
minimizing the treatment and viral load whereas maximizing a good immune response.
Thus, to achieve this goal through above reward function coefficients c1, c2 and c3 must
be negative whereas, c4 should be positive.
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In case of Sanford Health Data, gender, race, baseline_BMI, parent_BMI,
and month4_BMI are the state variables and two treatments each at stages A1 and A2
are the actions. Then here in this model we can define the reward function as:
𝑅2 (𝑆, 𝐴) = 𝛽1 𝑆𝑔 + 𝛽2 𝑆𝑝 + 𝛽3 𝑆4 + 𝛽4 𝐴2 (𝑆𝑝 + 𝑆4 )
𝑅1 (𝑆, 𝐴) = 𝛽5 𝑆𝑔 + 𝛽6 𝑆𝑟 + 𝛽7 𝑆𝑝 + 𝛽8 𝑆𝑏 + 𝛽9 𝐴1 (𝑆𝑔 + 𝑆𝑝 )

(3.3)
(3.4)

Equation (3.3) denotes the second stage reward function or which can also be viewed
as second stage value function in Q-learning algorithm that will be discussed later. In
this reward function, Sg, Sp and S4 are the state variables representing gender,
parent_BMI and month4_BMI respectively. Similarly, A2 is the treatment action
undertaken at stage 2 and 𝛽1 , 𝛽2 , 𝛽3 , 𝛽4 are the coefficients of respective state variables.
Additionally, as we have considered a two stage SMART trial design there should be a
reward function defined for stage 1 of trial assignment as well which is denoted by
equation (3.4). In this function, state variables Sr and Sb representing race and
baseline_BMI are included and A1 defines the treatment action taken at stage 1 also,
𝛽5 , 𝛽6 , 𝛽7 , 𝛽8 , 𝛽9 gives the coefficients for each of state variables and interaction
between them. Now, the next goal is to estimate these coefficients through regression
analysis and then approximate the above functions or estimate the values for interaction
between action space and state space.
3.2.1.4 Function Approximation Algorithm
After the representation of state and action space, choice of favorable time
horizon and assignment of effective reward function, we further need to implement one
of the many RL algorithms for representing and estimating the value function. In case
of continuous state space and discrete action space with appropriate dimension we can
use a simple tabular Q-function approximation algorithm. Also, in case of high
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dimensional dataset it is beneficial to use methods which can eradicate the issues that
can occur due to this high dimensionality and heterogeneity of the data. However, in
both cases we need to be sure about selecting the proper state space variables and
perform efficient trial assignment for good approximation of these value functions.
As we described previously that Q-learning is an efficient reinforcement
learning technique that is used to estimate and maximize the value function and this
algorithm also estimates the policy that maximizes the value of expected future reward
by relating the state and action space through function approximation.
First, to elucidate the idea, we will describe Q-learning for two treatment stages
and then also generalize it to K stages (𝐾 ≥ 2). Q-learning algorithm involves
backward induction process so the function approximation of last intervention or
second stage in our case is initiated at first, this serves to control for effects of both past
and subsequent adaptive intervention options. In a two-stage SMART study, training
data for a single patient follows the trajectory 𝐷 = {(𝑋1,𝑖 , 𝐴1,𝑖 , 𝑋2,𝑖 , 𝐴2,𝑖 , 𝑌𝑖 )}𝑛𝑖=1 . Where
the longitudinal data D consists of independent identically distributed copies of the
quintuple (𝑋1 , 𝐴1 , 𝑋2 , 𝐴2 , 𝑌), that gives the data collected on single subject [14]. Each
quintuple is called trajectory as they are time ordered, for example, if a trajectory
defined as 𝑋1 ∈ ℝ𝑝1 is the baseline covariate information, then 𝐴1 ∈ {−1,1} is the first
treatment option, 𝑋2 ∈ ℝ𝑝2 is the covariate information collected between first and
second treatment assignments, denoting predictive variables, 𝐴2 ∈ {−1,1} is the second
stage treatment and finally, 𝑌 ∈ ℝ is the primary outcome response variable or terminal
reward. Y1 and Y2 can be observed at the end of each stage in two-stage DTR policy,
however, in case of single terminal outcome Y can be viewed as a reward where Y1=0
and Y2=Y. The baseline covariates are the quantitative or qualitative variables that are
measured before randomization process which influences the value of primary outcome
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variable, Y that is to be analyzed [72]. For notational easiness and compactness, we
represent information available prior to the tth treatment assignment by Ht. Hence,
H1=X1 and 𝐻2 = (𝑋1𝑇 , 𝐴1 , 𝑋2𝑇 ) 𝑇 . As we consider a two-stage intervention we need to
define two stage Q-functions as:
𝑄2 (ℎ2 , 𝑎2 ) = 𝐸(𝑌|𝐻2 = ℎ2 , 𝐴2 = 𝑎2 )

(3.5)

𝑄1 (ℎ1 , 𝑎1 ) = 𝐸(𝑚𝑎𝑥𝑎2 ∈{−1,1} 𝑄2 (𝐻2 , 𝑎2 )|𝐻1 = ℎ1 , 𝐴1 = 𝑎1 )

(3.6)

Thus, a two-stage DTR consists of two decision rules suppose, (d1, d2) where 𝑑𝑗 (𝐻𝑗 ) ∈
{−1,1}. Now, to estimate the optimal DTR, 𝑑 𝑜𝑝𝑡 = (𝑑1𝑜𝑝𝑡 , 𝑑2𝑜𝑝𝑡 ) first, we need to define
the optimal Q-functions for two stages treatment decisions which can denoted as
follows:
𝑄2𝑜𝑝𝑡 (ℎ2 , 𝑎2 ) = 𝐸[𝑌2 |𝐻2 = ℎ2 , 𝐴2 = 𝑎2 ]

(3.7)

𝑄1𝑜𝑝𝑡 (ℎ1 , 𝑎1 ) = 𝐸[𝑌1 + 𝑚𝑎𝑥𝑎2 𝑄2𝑜𝑝𝑡 (ℎ2 , 𝑎2 )|𝐻1 = ℎ1 , 𝐴1 = 𝑎1 ]

(3.8)

After approximating above Q-functions using regression analysis which will be
discussed later we can estimate the optimal DTR i.e. (𝑑1𝑜𝑝𝑡 , 𝑑2𝑜𝑝𝑡 ), using backward
induction as in dynamic programming as:
𝑑𝑗𝑜𝑝𝑡 (ℎ𝑗 ) = arg 𝑚𝑎𝑥𝑎𝑗 𝑄𝑗𝑜𝑝𝑡 (ℎ𝑗 , 𝑎𝑗 ) , 𝑗 = 1,2

(3.9)

In general, function Qt (ht, at) measures the quality of treatment 𝑎𝑡 when this
treatment is assigned to a patient with history ℎ𝑡 . Here, the Q- functions at both stages
are defined as unknown conditional expectations where second stage Q-function,
𝑄2 (ℎ2 ,𝑎2 ) is the conditional expectation of potential response Y when treatment 𝑎2 is
assigned to a patient with history ℎ2 . Similarly, in stage 1 Q-function, 𝑄1(ℎ1 ,𝑎1 )
measures the quality of assigning treatment 𝑎1 to the patient with characteristics defined
by set ℎ1 , where, the predicted future outcome 𝑌̃is given by the maximum value of
𝑄2 (ℎ2 ,𝑎2 ) i.e.𝑌̃ = 𝑚𝑎𝑥𝑎2 ∈{−1,1} 𝑄̂2(ℎ2 ,𝑎2 , 𝛽̂2 ). To obtain the values of these unknown
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conditional expectations we can use linear regression model for curve fitting or function
approximation, it is common practice to use linear model for Q-functions represented
𝑇
𝑇
as: 𝑄𝑡 (ℎ𝑡 ; 𝑎𝑡 ; 𝛽𝑡 ) = ℎ𝑡,0
𝛽𝑡,0 + 𝑎𝑡 ℎ𝑡,1
𝛽𝑡,1 , where ℎ𝑡,0and ℎ𝑡,1 are the same subvectors
𝑇
𝑇 𝑇
of ℎ𝑡 and 𝛽𝑡 = (𝛽𝑡,0
, 𝛽𝑡,1
) . The Q-learning algorithm using linear models for the Q-

functions can be summarized in following three steps:
•

Estimate 𝛽2 and then, Q2 via least-squares regression of Y on H2 and A2 using
the following model:
𝑛

𝛽̂2 = arg 𝑚𝑖𝑛𝛽2 ∑{𝑌𝑖 − 𝑄2 (𝐻2,𝑖 , 𝐴2,𝑖 ; 𝛽2 )}2

(3.10)

𝑖=1

•

Calculate predicted future outcomes 𝑌̃ assuming optimal second-stage
decisions,
𝑇 ̂
𝑇 ̂
𝑌̃ = 𝑚𝑎𝑥𝑎2 ∈{1,−1} 𝑄2 (𝐻2 , 𝑎2 ; 𝛽̂2 ) = 𝐻2,0
𝛽2,0 + |𝐻2,1
𝛽2,1 |

(3.11)

Then estimate 𝛽1 , and hence Q1, again using least-squares regression of 𝑌̃ on
H1 and A1 using the model,
𝑛

𝛽̂1 = arg 𝑚𝑖𝑛𝛽1 ∑{𝑌̃𝑖 − 𝑄1 (𝐻1,𝑖 , 𝐴1,𝑖 ; 𝛽1 )}2

(3.12)

𝑖=1

•

Calculate the estimated Q-learning optimal treatment policy, 𝑑𝑗𝑜𝑝𝑡 =
(𝑑1𝑜𝑝𝑡 , 𝑑2𝑜𝑝𝑡 ) as,
𝑑𝑗𝑜𝑝𝑡 = arg 𝑚𝑎𝑥𝑎2 ∈{−1,1} 𝑄𝑡 (ℎ𝑡 , 𝑎𝑡 , 𝛽̂𝑡 )

(3.13)

Now, the above process can be generalized to K>2 number of stages, where first
we need to define the optimal Q-function by using backward induction as:
𝑜𝑝𝑡
𝑄𝑗𝑜𝑝𝑡 (𝐻𝑗 , 𝐴𝑗 ) = 𝐸 [𝑌𝑗 + 𝑚𝑎𝑥𝑎𝑗+1 𝑄𝑗+1
(𝐻𝑗+1 , 𝑎𝑗+1 )|𝐻𝑗 , 𝐴𝑗 ] ,

𝑗 = 1, … , 𝐾

(3.14)
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Also, for values of j=K, K-1, …, 1, as we are moving backward through the stages the
regression parameter can be estimated using:
𝑛

1
𝑜𝑝𝑡
𝛽̂𝑗 = arg 𝑚𝑖𝑛𝛽𝑗 ∑(𝑌𝑗𝑖 + 𝑚𝑎𝑥𝑎𝑗+1 𝑄𝑗+1
(𝐻𝑗+1 , 𝑎𝑗+1 ; 𝛽̂𝑗+1 ) − 𝑄𝑗𝑜𝑝𝑡 (𝐻𝑗𝑖 , 𝐴𝑗𝑖 ; 𝛽𝑗 ))2 (3.15)
𝑛
𝑖=1

Finally, the optimal DTR for K stages, i.e. (𝑑̂1𝑜𝑝𝑡 , … , 𝑑̂𝐾𝑜𝑝𝑡 ) can be obtained as:
𝑑̂𝑗𝑜𝑝𝑡 (ℎ𝑗 ) = arg 𝑚𝑎𝑥𝑎𝑗 𝑄𝑗𝑜𝑝𝑡 (ℎ𝑗 , 𝑎𝑗 ; 𝛽̂𝑗 ),

𝑗 = 1, … , 𝐾

The Flowchart for above mentioned algorithm is presented as follows:
Training data for 2-stage randomization design:
𝐷 = {(𝑋1,𝑖 , 𝐴1,𝑖 , 𝑋2,𝑖 , 𝐴2,𝑖 , 𝑌𝑖 )}𝑛𝑖=1
History set: 𝐻𝑡 = (𝑋𝑡−1 , 𝐴𝑡 , 𝑋𝑡 )

Regression analysis:
Linear model for Q-function:
𝑇
𝑇
𝑄𝑡 (ℎ𝑡 , 𝑎𝑡 ; 𝛽𝑡 ) = ℎ𝑡,0
𝛽𝑡,0 + 𝑎𝑡 ℎ𝑡,1
𝛽𝑡,1

Two stage Q-functions:
𝑄2 (ℎ2 , 𝑎2 ) = 𝐸(𝑌|𝐻2 = ℎ2 , 𝐴2 = 𝑎2 )
𝑄1 (ℎ1 , 𝑎1 ) = 𝐸(𝑚𝑎𝑥𝑎2 ∈{1,−1} 𝑄2 (ℎ2 , 𝑎2 )|𝐻1 = ℎ1 , 𝐴1 = 𝑎1 )

Q-learning Algorithm:
Q1. Modeling: Regress Y on H20, H21, A2 to obtain
𝑇 ̂
𝑇 ̂
𝑄̂2 (𝐻2 , 𝐴2 ; 𝛽̂2 ) = 𝐻20
𝛽20 + 𝐴2 𝐻21
𝛽21

Q2. Maximization: Define 𝑌̃ = 𝑚𝑎𝑥𝑎2 ∈(−1,1} 𝑄̂2 (𝐻2 , 𝑎2 , 𝛽̂2 ).
𝑇 ̂
𝑇 ̂
𝑌̃ = 𝐻20
𝛽20 + |𝐻21
𝛽21 |, is the predicted future outcome
assuming an optimal decision is made at stage two.

Q3. Modeling: Regress 𝑌̃ on H10, H11, A1 to obtain
𝑇 ̂
𝑇 ̂
𝑄̂1 (𝐻1 , 𝐴1 ; 𝛽̂1 ) = 𝐻10
𝛽10 + 𝐴1 𝐻11
𝛽11 .

(3.16)
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𝑜𝑝𝑡

Estimate Q-learning optimal treatment policy: 𝑑𝑗
𝑜𝑝𝑡 𝑜𝑝𝑡
(𝑑1 , 𝑑2 )
𝑜𝑝𝑡

𝑑𝑗

=

as:

= arg 𝑚𝑎𝑥𝑎2 ∈{1,−1} 𝑄𝑡 (ℎ𝑡 , 𝑎𝑡 , 𝛽̂𝑡 )

Figure 3.2. Flowchart for Regression analysis and Q-learning estimation
3.3 Model Implementation
3.3.1 Framework on Sanford Health Data
Profile by Sanford is a personalized weight management plans that
combines healthy grocery food with nutritious meal replacement products. These plans
are created by physicians and researchers. In this weight management plans, there are
mainly three core principles, which are:
•

Nutrition

•

Activity

•

Lifestyle

The Profile is a personalized plan as the meal plan and activities are developed for each
profile member. The main steps involved in this weight management plans are:
•

Reduce, in which food with low carbohydrate but high protein is given to
the patients.

•

Adapt, where more healthy foods are introduced after certain period of time.

•

Sustain, where the lost weight is maintained by means of exercise and
careful diet.

Major protocols in personalized meal plan under Profile by Sanford can be listed as
follows:
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•

Reboot Protocol:
The reboot Protocol focuses the body to burn the stored fats by means of
physical exercise or meal replacements. There are mainly five profile meal
replacement plans consisting of lean and green evening meals, snacks and
vegetables.

•

Balance Protocol:
The Balance protocol takes in consideration the members or patients with
special medical or Dietary requirements and takes a balanced approach
accordingly.

•

Additional Protocol:
This protocol provides special plans for pregnant and nursing moms as
well as teens who are obese.
The Sanford Profile data used for this research needed a serious

restructuring for obtaining an appropriate training dataset which would be conducive
for application of algorithm that can estimate the optimal DTR. Initially, the dataset
consisted of patients’ id, their respective weights and the date these weights were
recorded. On the top of that the weights were not even arranged according to patients’
id, so, one patient’s weight taken at point t1 may appear at top of dataset whereas that
taken at different point t2 may appear later in it. Thus, the first modification needed was
on the dataset, to arrange the weights according to their respective user-id or patient’s
id. After this modification was performed using MATLAB different state variables
were further added along with weights measured at baseline (before any treatment is
administered), after 4 months (after treatment at first stage) and after 12 months (after
second stage treatment). Similarly, the BMI of each patients for each measured weight
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was also calculated using equation (3.17) and also the treatment options at each
treatment stages were randomized for every subject.
𝐵𝑀𝐼 =

𝑚𝑎𝑠𝑠𝑙𝑏
2 × 703
ℎ𝑒𝑖𝑔ℎ𝑡𝑖𝑛

(3.17)

Figure 3.2, shows the initial dataset by Sanford Profile which required a serious
arrangements and restructuring. Arrangement of weights according to respective
patient’s id was performed using Matlab programming which involved using cell
format for each patient and also noting the weights after 4 months and 12 months
according to the dates of weight measurement available in the dataset. After, the
arrangement the restructuring process the dataset is shown in figure 3.3, where in first
column the patient id was arranged and second column gave the respective weight in lb
taken at date given by the third column.
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Figure 3.3. Initial Profile by Sanford dataset that required a serious restructuring.

Figure 3.4. Arranged and restructured Sanford dataset.
Figure 3.3, only shows the raw form of arranged dataset with only weights
as possible state variable. However, there is need of additional state variables and
further the BMI for each patient so that the relationship between these variables and the
response can be implemented using RL algorithm and Q-learning for estimating
optimal DTR. The whole training dataset that meets all above requirements along with
the results from employing the algorithm will be described in the result and discussion
chapter, Chapter 4.
3.3.2 R environment and coding
The Q-learning algorithm is implemented in R environment for estimating
optimal DTR using the package iqLearn [75], which can be used with dataset from twostage SMART trial design with binary treatments at each treatment stages. The dataset
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used was obtained from Sanford Health that contained the weight of patients measured
at different time periods and the study was to observe the effect of meal replacement
plans on adolescent obesity. This dataset consists of four covariates information at the
start of first stage namely, gender, race, parent_BMI and baseline_BMI. Similarly, at
second-stage or after the first treatment is administered, co-variate “month4_BMI” is
collected. The treatment variables are denoted by “A1” and “A2” for first and second
treatment stages, respectively. The primary outcome “month12_BMI” is observed at
the end of stage two.
In Q-learning the function “qLearnQ1” recommends the estimated optimal
treatment for first-stage with history set h1. Similarly, function “qLearnQ2”
recommends the optimal treatment for second-stage having history, h2. The residual
plots can be accessed for regression using “plot.qLearnS1” and “plot.qLearnS2” for
first stage and second stage regression, respectively. The outcome of these residual
plots will be discussed in chapter 4. Further, the plug-in value of any treatment decision
rule can be estimated using the function “value”. This function gives the estimated
values of all possible treatment decisions rules embedded in the SMART design. Thus,
the decision rule yielding maximum plug-in value is chosen as the optimal decision
rule. Similarly, The adequateness of regression analysis or closeness of regression line
fit can be observed and analyzed by using “summary” command. This will give us all
the values of regression coefficients or parameters involved in the regression equation
along with the R-squared value.
Therefore, for Q-function approximation and estimation of optimal
decision rule R-software environment was favorable as it enables one to perform both
graphical and statistical analysis of fit adequacy of a regression model and verify the
underlying assumptions [73].
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3.4 Optimization Assumptions and Residual Analysis
The multiple regression analysis is a statistical tool for analyzing and modeling
the relationship between dependent and independent variables. The simple model for
linear regression can be considered as 𝑦 = 𝛽0 + 𝛽1 𝑥 + 𝜀, where x is the independent
variable and y the dependent variable. The independent variable is considered as
predictor or regressor variable whereas dependent variable is the response variable. The
term 𝜀 in the model gives the difference between the observed value and the predicted
value by the model and is known as error. To obtain close fit of regression line the error
term 𝜀 should be minimized.
Now, there are some important assumptions that are needed to be established
before employing simple linear regression in the mathematical model. These
assumptions help to define the criteria for verifying the results and also to underpin the
notion that errors are independent random variables and requirement of hypothesis
testing and interval estimation. The main assumptions in the study of simple linear
regression analysis are listed below [74]:
•

The relationship between the response variable y and the corresponding
regressor variables should be approximately linear.

•

The error term 𝜀 has zero mean.

•

The error term 𝜀 has approximately constant variance 𝜎 2 .

•

The errors are independent.

•

The errors follow normal distribution.

For examining the adequacy of the model, the validity of above assumptions should be
met and if these assumptions are violated the linear model can be infected by various
model inadequacies resulting serious consequences in model fit. The violation of these
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assumptions can lead us to an unstable model where providing different sample leads
to varying model or results with conflicting conclusions. One of the diagnostic method
for examining the violations of these regression assumptions if to study the residuals of
the model.
Therefore, residual analysis is not only a prominent way for checking the
violation of linear regression assumption and adequacy of model fit but also a standard
approach that should be followed while using regression based method, such as Qlearning, for function approximation to estimate DTR [75, 76]. So, first to define the
residuals in regression analysis, consider first the following expression:
𝑒𝑖 = 𝑦𝑖 − 𝑦̂𝑖 ,

𝑖 = 1,2, … , 𝑛

(3.18)

Where 𝑦𝑖 is the observed or real value of the dependent variable that is obtained from
the training dataset, and 𝑦̂𝑖 is the corresponding fitted value or the predicted value by
the model. Then, as equation (3.18) suggests the residual can be defined as the deviation
between the value of the response variable that is obtained from the training data and
that obtained from the fitted value in the regression model. Thus, analysis of residuals
can help in examining above assumptions as residuals define the error between the
realized value from the model and the observed value in the data. Several model
inadequacies can be detected by plotting residuals and observing the violation of
assumptions which leads to an effective investigation of if the regression model fits the
training data satisfactorily and if the assumptions of linear regression analysis are met.
To properly understand the process of residual analysis the basic properties of
residuals should be understood. The important property of residual is that their mean is
zero, and the approximate average variance is estimated as:
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∑𝑛𝑖=1(𝑒𝑖 − 𝑒̅ )2 ∑𝑛𝑖=1 𝑒𝑖2 𝑆𝑆𝑅𝑒𝑠
=
=
= 𝑀𝑆𝑅𝑒𝑠
𝑛−𝑝
𝑛−𝑝
𝑛−𝑝

(3.19)

Where 𝑛 − 𝑝 gives the degree of freedom associated with the n residuals and p is the
number of parameters. The residuals are independent of each other and the residual
values can be scaled. Standardized residuals are one of the process for scaling the
residuals which is useful for finding the observations that are ouliers or extreme values
in which the observations are separated from the core part of data in some way.
The average variance of residuals in data is approximated by 𝑀𝑆𝑅𝑒𝑠 , which is
given by equation (3.19), using the value of 𝑀𝑆𝑅𝑒𝑠 from it the values of residuals using
standardized residuals, can be scaled as:
𝑑𝑖 =

𝑒𝑖
√𝑀𝑆𝑅𝑒𝑠

,

𝑖 = 1,2, … , 𝑛

(3.20)

The values of standardized residuals have approximately unit variance and contain a
mean of zero. The data point with large standardized residual say, di>3 denotes a
potential outlier.
Model checking using Residual Diagnostic plots was introduced by Henderson
et al. in 2010 [77], which was used for checking model misspecifications for estimating
optimal DTR. As mentioned earlier, graphical analysis of residuals is very effective
way to analyze the fit adequacy of a regression model and check the underlying
assumptions. The residual diagnostic plots at each stage of regression presents the plots
between residuals and fitted values, normal Q-Q plot, scale location plot and residual
vs leverage plot. The plot between residual and fitted values shows if residuals have
non-linear patterns and normal Q-Q plot shows if residuals are normally distributed.
Similarly, scale-location plot checks the assumption of constant variance of residuals
and residuals vs leverage checks to find out influential cases if any. These all plots are
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meant to check if above listed assumptions for linear regression models are violated or
not to access a good fit. In the model, there are two stages and two subsequent
regression analysis with residuals defined as difference between potential final outcome
and outcome form the estimated Q-functions.
3.5 Sampling for Model Validation
The model validation is one of the most important step in a mathematical model
building process which includes the process of measuring the extent of clinical benefit
while applying the treatment rule for future patients. Generally, there are two ways to
validate a model which are, external validation process and internal validation process.
The external validation process employs the training data for model building whereas
uses test or validation data to validate the model. On the other hand, the internal
validation uses the same single dataset for both model building and validating agendas.
Bootstrapping is one of the internal model validation process where samples are
generated from population dataset in which the samples are drawn with replacement.
Also, the sample size of both dataset is same and the validation process begins by
testing the model on these bootstrap samples.
The bootstrap as discussed earlier involves random sampling with, replacement
of data points from original dataset which are then later used for establishing statistical
inferences. Along with it the bootstrapping method can be used to approximate the
confidence intervals (CI) for estimated regression coefficients in a regression analysis.
For example, the 95% CI of a sample mean can be obtained by using following steps:
•

Let’s consider n observations with sample data points (𝑌1 , 𝑌2 , … , 𝑌𝑛 ), where 𝑌̅
gives the sample mean of this sample dataset.
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•

If SD is the standard deviation of sample then SE, the standard error of sample
mean is then:
𝑆𝐸 =

𝑆𝐷

(3.21)

√𝑛

The value of above SE gives the closeness of sample mean to the unknown
population mean.
•

Now, the 95% CI can be obtained by using the expression (𝑌̅ − 1.96 ∗ 𝑆𝐸, 𝑌̅ +
1.96 ∗ 𝑆𝐸).

•

As the sample size increases and as the sampling distribution of sampling mean
is closer to normality the CI moves closer towards the validity.
One of the very popular bootstrapping methods for computationally

constructing CIs is the double bootstrap method which was explained by Davison and
Hinkley in 1997 [75] and further implemented by Nankervis in 2005 [78]. In context of
estimating optimal DTR using Q-learning, Chakraborty et al. in 2010 [79] used double
bootstrapping method for estimating the CIs of the regression coefficients in multiple
regression model of Q-functions.
Now, in double bootstrap method first an estimator of a parameter and its
bootstrapped counterpart are defined. So, let 𝜃̂ be the estimator of parameter 𝜃 and 𝜃̂ ∗
be the bootstrap version of that estimator. Then as it is known from above that the
100(1 − 𝛼)% percentile bootstrap CI is given by (𝜃̂ ∗ (𝛼) , 𝜃̂ ∗ (1−𝛼) ), where 𝜃̂ ∗ 𝛾 is the
2

2

100𝛾 𝑡ℎ percentile of the bootstrap distribution. Then the double bootstrap CI was
calculated as follows:

60
•

A first set of bootstrap samples say B1 from original dataset was constructed.
For this sample, the bootstrap version of estimator 𝜃̂ ∗𝑏 was estimated, where
b=1,…, B1.

•

Depending on first set of bootstrap samples, i.e. B1 the second set of bootstrap
samples, B2 was constructed and the double bootstrap version of
estimator, 𝜃̂ ∗∗𝑏𝑚 was calculated, where, b= 1,…, B1 and m=1,…,B2.

•

1
𝐵2
The value of 𝑢∗𝑏 = 𝐵 ∑𝑚=1
Ι[𝜃̂ ∗∗𝑏𝑚 ≤ 𝜃̂] was estimated, where 𝜃̂ is the
2

estimator obtained from original data.
•

Now, lastly the double bootstrap CI was obtained by calculating the interval
∗
(𝜃̂ ∗ 𝑞̂(𝛼) , 𝜃̂ ∗ 𝑞̂(1−𝛼) ), where 𝑞̂(𝛾) = 𝑢(𝛾)
or the 100𝛾 − 𝑡ℎ percentile of
2

2

distribution 𝑢∗𝑏 , b = 1,…, B1.
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CHAPTER 4
RESULTS AND DISCUSSION
4.1 Results from Sanford Health Data
4.1.1 Data Restructuring
The data obtained from Sanford Health needed a critical restructuring to
make it conducive for implementing SMART design and further Q-learning for
optimization process. As mentioned in previous chapter the received dataset only
consisted of user_id or patient’s id along with their respective weights and date the
weight was measured, however, the data were not arranged and required the weights
taken after 4 months and 12 months. As, all patients were not able to continue the
treatment for whole year or in other words there were some dropouts before 12 months
period, only 210 patients data were selected for analysis who continued their treatment
until 1 year period or more.
Furthermore, covariates such as gender, race, height, parent’s BMI and
treatment decisions at each stage were randomized and annexed to the restructured
dataset. According to the heights assigned to each patients the BMI after 4 months and
after 12 months of treatment were calculated using the equation (3.17). Thus, the
restructured data consists of 210 rows of patients and 9 columns of covariates and some
head rows of the dataset can be observed below in figure 4.1.
The restructured dataset of figure 4.1, consists of required input covariates
and treatment decisions for each stages of a two-stage SMART design. The data are
restructured in a way where inputs to the first stage regression analysis are gender, race,
parent_BMI and baseline_BMI and that to the second stage regression analysis are
again gender, parent_BMI and month4_BMI along with the treatment decisions A1 and
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A2 for first stage and second stage treatments respectively. After, restructuring of data
the multiple regression was employed for approximating the functions for second stage
and first stage of SMART design. The summary and discussion of the regression
analysis is described next.

Figure 4.1. The head rows of restructured dataset consisting of randomized covariates
and required BMI information for implementing SMART design.
4.1.2 Initial Data Assessment
The initial assessment was performed on the restructured dataset where
first response after 12 months was observed for female and male and race A and race
B (races under comparison) using box-plots. Similarly, box-plots were again used to
observe the effect of treatments (e.g. Augment and Switch) on response after 4 months
and after 12 months.
In figure 4.2, for data following a normal distribution, the mean value of
BMI after 12 months for female is lower than that for male. Similarly, race B has lower
mean value for BMI after 12 months compared to race A. Additionally, comparing
response after 4 months for treatment stage 1, there is not much difference in average
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BMI between treatments augment and switch. However, for second stage the average
BMI after 12 months decreases for treatment augment compared to switch.

Figure 4.2. Box-plots of response after 4 months and 12 months according to gender,
race and treatment decisions at each stage.
After average BMI for 4 months and 12 months response were observed
according to gender, race and treatment stages using Box-plots, scatter-plots matrix was
used to observe relationship between response and predictors. First the relation between
second stage response variable, month12_BMI was compared with predictors
parent_BMI, baseline_BMI and month4_BMI.
From figure 4.3, it can be clearly observed that the response month12_BMI has
a strong linear relationship with the predictors baseline_BMI and month4_BMI. This
also validates the case of linear model being employed for estimating Q-function for
stage 2 regression analysis. Similarly, figure 4.4, below shows the relation between
response i.e. month4_BMI and predictors which also has a strong linear relationship
and linear model is defined for first stage regression analysis too.
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Figure 4.3. Scatter-matrix plots for second-stage regression predictor and response
variables showing a linear relationship.

Figure 4.4. Scatter-matrix plots for first-stage regression predictor and response
variables showing a linear relationship.
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4.1.3 Regression Analysis
The multiple regression is implemented initially to second stage of
SMART design as Q-learning is a backward induction method. In second stage, as
mentioned earlier the input to the regression formula are gender, parent_BMI,
month4_BMI and treatment decision (A2). The stage two multiple regression model
equation is represented below as:
y = 𝛽0 +𝛽1gender+𝛽2 parent_BMI+𝛽3month4_BMI+A2*(𝛽4
parent_BMI+𝛽5month4_BMI)

(4.1)

In above equation 𝛽1 , 𝛽2 , 𝛽3 , 𝛽4 , 𝛽5 are the coefficients of the independent variables
gender, parent_BMI, month4_BMI and interactions between parent_BMI and
month4_BMI respectively. Also, y is defined as the negative percent change in BMI at
month 12 from baseline BMI i.e., 𝑦 = −100 ∗ (

𝑚𝑜𝑛𝑡ℎ12𝐵𝑀𝐼 −𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒𝐵𝑀𝐼

).Now, the goal

𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒𝐵𝑀𝐼

is to estimate these coefficients so that the function given by the equation (4.1) can be
approximated. After applying the multiple regression, following summary for second
stage was obtained:
Table 4.1 Summary table for stage 2 regression analysis
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The information about estimated values of regression coefficients, residuals, standard
error of estimated coefficients and other such as R-squared error can be obtained from
above Table 4.1.
Furthermore, in simple linear regression model the coefficients are the constants
that represent the intercept and the slope of the linear model. The first column
“Estimate” of the table coefficients gives the estimates of all the expected values of the
coefficients as described by equation (4.1). Similarly, the second column “Std. Error”
gives the error in estimated coefficients. The lower values of this standard error suggest
good quality of regression line fit. The t value on the third column gives the measure
of how many standard deviations is the estimated coefficients away from 0. Further the
distance closer to decision rule of rejecting null hypothesis, enabling the declaration of
strong relationship between predictor variables and the response variable. The asterisk
(*) alongside the values represent the level of significance three being the most
significant estimate. Finally, the column “Pr (>t)” describes the probability of
observing the value equal or greater than t value. The smaller p values in this column
suggests that the relationship that is observed between the predictor and response
variable is not by chance or fluke. Thus, these small p-values for estimates slope or
intercepts suggests that the null hypothesis can be rejected and concludes a good
relationship between treatment decisions and the patient co-variates.
Next, is the residual standard error that measures the quality of regression line
fit and is defined as the average distance or deviation of the response (treatment
outcome) variable from the linear regression line. As, the regression line cannot be
perfect, and every model is presumed to have some error term E and this error term
should be as minimum as possible so that the prediction is accurate and consistent.
From Table 4.1, after observing the error value of 0.63, it can be deduced that the
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predictor variable can deviate from the regression line approximately by this error term
on average during the prediction of response variable. Also, the degree of freedom
defines the number of data points that was taken into consideration while estimating
the regression parameters.
Similarly, the Multiple R-squared and Adjusted R-squared statistics also
provides the measure of closeness of fit between the model and its fitting to the actual
data. So, R2 term defines the measure of linear relationship between the independent
and response variable whose values lie between 0 and 1. If the value of this term is
closer to 0 than the regression line will poorly explain the variance in response variables
whereas values closer to 1 will provide good regression line fit. In case suggested by
above Table 4.1, approximately 88% of variance observed in response variable can be
well explained by the predictor variables. However, in multiple regression setting the
value of R2 increases as the number of predictor variable increases or as more variable
are introduces to the model. So, to minimize this effect the adjusted R2 is preferred more
as it considers and adjusts the effect of number of variables considered for regression
analysis.
Lastly, the F-statistic, as shown in table 4.1, can also be a good estimator of
relationship between the dependent and independent variables in a regression model.
As the value of this statistic moves further from 1 or is greater than 1 the better is the
model or it well explains the relationship. However, its value is also dependent upon
the number of variables considered on the model. Generally, if the number of data
points are small the value of F-statistic little bigger than 1 is sufficient in rejecting the
null hypothesis and accepting the notion that there is a good relationship between
predictor or response variable or good fit of regression model is obtained through
regression analysis. In case of second stage regression analysis for Q – function
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approximation 184.4, F-statistic value was obtained that is larger than 1 in relation to
size of data employed. So, from the results of second stage multiple regression model
it can be posited that there is good linear fit and the model can be implemented for
predicting treatment rule for future patients.
Now, Table 4.2, below shows the summary of regression analysis for function
approximation in stage 1 of SMART design. As Q-learning process follows backward
induction, the predicted future outcomes 𝑌̃ assuming an optimal decision was
prescribed in the second-stage, was calculated as follows:
𝑇 ̂
𝑇 ̂
𝑌̃ = 𝑚𝑎𝑥𝑎2 ∈{−1,1} 𝑄2 (𝐻2 , 𝑎2 ; 𝛽̂2 ) = 𝐻2,0
𝛽2,0 + |𝐻2,1
𝛽2,1 |

(4.2)

After predicting the future outcomes, the value of coefficients and error minimization
process was undertaken using least-square regression method and following summary
table was obtained:
Table 4.2 Summary table for stage 1 regression analysis
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As discussed for table (4.1), summary for second stage regression analysis, table
(4.2) shows the summary table for first stage regression. Here also, first the coefficients
of independent variables were estimated for the equation (4.2) as shown below:
y = 𝛽0+𝛽1gender+𝛽2race +𝛽3 parent_BMI+ 𝛽4 baseline_BMI+A1*(𝛽5 gender + 𝛽6
parent_BMI)

(4.3)

Similar to summary table (4.1), in table (4.2) the estimated coefficients of equation (4.3)
are listed. Using these estimates, the function can be approximated and used to compare
the Q-values for different set of covariates and treatment decisions and then finally the
optimal treatment decision can be estimated as it is the set of inputs that results in
maximum Q-value.
From table (4.2), the values of coefficient estimates, error while estimating these
coefficients and various other information about adequacy of regression line fit such as
Residual standard error and adjusted R-squared values can be obtained. The value of
1.847 was obtained for the residual standard error value during first stage regression,
this means that the values of independent variables can deviate from regression line by
value of 1.847. Similarly, the multiple R-squared error was 0.9549 and that for adjusted
one was 0.9531, referring to the statement that approximately, 95% of variable that is
observed in response variable can be well explained by the predictor variables. Also,
the F-statistic value of 534.6 was observed which is much greater than 1 and p-value
obtained was significantly lower than 1. Therefore, from these results it can be stated
that good linear fit was observed during regression analysis for first stage treatment
decision in SMART design and this estimated function can be implement while
prescribing first stage treatment for patients with totally different sets of input
covariates.
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4.1.4 Regression Diagnostic Plots
As mentioned in earlier chapters, the graphical analysis of residuals is very
effective way to analyze the adequacy of fit and to check the underlying assumptions
of any regression model. As residuals are the difference between the observed value
and predicted value from the model, there are mainly four plots that comes into
consideration while describing residual diagnostics and they are plot between residuals
and fitted values, the normal Q-Q plot, the scale-location plot and the residual versus
leverage plot. Now, each plot obtained for first and second stage multiple regression
analysis is described below.
First, the plot between residuals and fitted values shows if the residuals
have nonrandom patterns or not. This plot is also useful for verifying the assumptions
made for linearity and homoscedasticity (constant variance assumption). In this
scenario, the model said to not meet the linear model assumption, if very large residuals
with big positive or negative value were observed. So, these residuals should not be
very far from 0 so that the assumption of linearity is met, similarly, it was also needed
to make sure that there is no pattern observed or the residuals are equally spread around
line y=0 for accessing the assumption of homoscedasticity. The residual versus fitted
plot for second stage regression analysis is shown below:
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Figure 4.5 Residual versus fitted plot for second stage multiple regression

Figure 4.5, shows the residuals versus fitted plot for multiple regression while
prescribing second stage treatment decision in SMART design. From the plot, it can be
observed that the residuals are homogenously spread above and below 0 and no pattern
can be observed for residual vs fitted line. Thus, both the assumptions of linearity and
homoscedasticity were met. Again, for first stage regression analysis following plot was
obtained:

Figure 4.6 Residual versus fitted plot for first stage multiple regression
Figure 4.6, shows the plot between residual and fitted values for multiple regression in
first stage of treatment decision using SMART design. From this plot, it can be
observed that again the residuals are uniformly distributed along 0 and there is no
pattern if a line is drawn for fitting the data points. Thus, in case of first stage regression
also the assumptions of linearity and homoscedasticity were met.
Next, the normal Q-Q plot for both first and second stage regression were
investigated for evaluating the normality assumption of linear regression which
basically, compares the standardized residuals to theoretical quantiles or normal
observations. If the observations follows or lies along the 45-degree line then it can
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deduced that the normality assumptions hold. It can also be observed from following
figure 4.7, which shows the Q-Q normal plot for second stage regression analysis.

Figure 4.7 Normal Q-Q plot for second stage multiple regression analysis
Figure 4.7, shows that most of the observations follows or lies on the 45-degree dotted
line hence, the normality assumption is validated for linear regression. Also, it can be
asserted that for a linear regression analysis the model fitting is good and assumption
of normality is observed. Again, the normal Q-Q plot for first stage regression analysis
is shown below:

Figure 4.8 Normal Q-Q plot for first stage multiple regression analysis

73
Figure 4.8, shows the normal Q-Q plot for multiple regression analysis while
prescribing treatments for first stage in SMART design. Here, also much of the
observations are in the 45-degree line and the analysis can be asserted to the point that
normality assumption of the linear regression holds in this case too and the regression
fit is good.
Further, to validate the assumption of homoscedasticity which states that, the
variance of residuals is constant for any different predictor values, in linear regression
model fitting procedure scale-location plot can be used to check if there is some pattern
or if the variance is constant for values of independent variables. The scale-location
plot is plotted between the square rooted values of standardized residuals and predicted
values from the model. Following figure, figure 4.6 shows the scale-location plot for
predictor values of second treatment decision stage in SMART design which is used to
estimate optimal DTR.

Figure 4.9 Scale-Location plot for second stage regression analysis

In Figure 4.9, the plot examines if the residuals are equally spread along the different
ranges of predictor variables. Therefore, as it can be observed in figure 4.6, a horizontal
line with equally spread random points along it can be conjectured that the variance of
residuals is constant and hence, the assumption of homoscedasticity is validated. Also,
the scale-location plot for regression analysis in first stage of treatment decision is
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shown in figure 4.10 below. In the figure 4.10, it can be observed that the variance is
again constant along different values of predictor variables and the assumption of
homoscedasticity is valid in this case too. Thus, both of the plots strengthen the
conjecture of good regression model fit and underpins the significance of approximated
functions, while implementing these functions as base of prescribing treatments in two
consecutive stages suggested by the SMART design in our model.

Figure 4.10 Scale-Location plot for first stage regression analysis
Lastly, for the next graphical analysis which considers the “Cook’s distance” to
measure the influence of each observation while predicting the values of regression
coefficients, the following terms should be defined:
•

The observations with large residuals compared to other observations in the
model are known as outliers. For example, if the observed value of one of the
observation is very much different than that of the predicted value obtained
using regression model, then this observation can be categorized as an outlier.

•

Next, the leverage points of each observation are needed to be considered while
analyzing the goodness of model fit. A leverage point can be defined as the
distance of an observation from its mean value.

•

Also, the observation with significant leverage can change the slope of
regression line resulting this observation to be very influential. Hence, these
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influential points have substantial influence on goodness of fit in any regression
model.
Now, the graphical analysis of plots between leverage and standardized residuals also
defines a statistic measure term called “Cook’s distance”. The Cook’s distance
measures the influence of an observation on the overall regression model for example
change in regression coefficients. Thus, this statistical tool analyzes the amount or
extent of changes that occurs in model if an observation is omitted. Generally, the
observations with high influence on the model has cook’s distance close to one or larger
compared to other observations. Figure 4.11 below shows the residual versus leverage
plot for second stage regression analysis in SMART design. From the plot, it can be
observed that the model is not affected by influential points majority of observations
lie within 1 cook’s distance. Therefore, the model for regression analysis in second
stage treatment decision is not affected by the influential points.

Figure 4.11 Residuals vs Leverage plot for second stage multiple regression analysis
Similarly, the residual versus leverage plot for first stage regression is also shown in
figure 4.12, below. Also, from figure 4.12, it can be observed that no observations have
cook’s distance greater or equal to 1 and there are no major influential observations.
However, the regression line is stretched due to the observations with high leverage,
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but the influential points are minimal so that they will not affect the overall regression
model.

Figure 4.12 Residuals vs Leverage plot for first stage multiple regression analysis

Therefore, from above residual diagnostics, it can be deduced that the coefficients
which were estimated for regression function are correctly specified as the assumptions
of linear regression analysis are verified using residual diagnostic plots.
4.1.5 Optimal Treatment Decision Rule
Now, after the Q-functions at both treatment stages are approximated using
multiple regression method, the other set of input covariates from new patient can result
in output which is treatment resulting maximum Q-value at respective stages. For
example, in stage 1 the problem is to prescribe an optimal treatment for patient with
new set of input covariates, thus, to do that first the values of Q-functions are
approximated for each available treatment options and the one resulting maximum Qvalue is defined as the optimal treatment decision.
Table 4.3 Optimization of adaptive decision rule according to maximum value of Qfunctions
Combination of history set

Treatment = 1

Treatment = -1

Optimal Treatment

Q2 value, c (1,30,24)

0.3803014

-0.01900676

1
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Q1 value, c (1,0,34,30)

1.023668

1.23254

-1

Q2 value, c (1,30,45)

-0.9962029

-0.8904261

-1

Q1 value, c (1,0,25,30)

-2.055502

2.866527

-1

Table 4.3, above shows different values of Q-functions at stages Q2 and Q1, where the
inputs are distinct set of biomarkers belonging to a fresh patient or patient having first
clinic visit. Thus, the set of biomarkers or history set for these patients are given as
input to the model and defined as the argument of set c, for example, c (1,30,24) in first
row gives the information about gender, BMI after four months and BMI after 12
months, respectively of a new patient in program. Using this information, a history set
is constructed and is used for estimating the values of Q-functions by keying the history
set values as inputs or values of predictor variables in the approximated Q-functions of
the model. As the values of regression coefficients are already approximated through
regression analysis, the Q-functions values for newly constructed history set can be
easily estimated using these biomarkers of a new patient.
Furthermore, the Q-values at each treatment stages are noted for assigned
treatment decisions (1 or -1) in that particular stage and the treatment resulting in
maximum Q-value is selected as optimal treatment decision. It can be observed in table
4.3 that in stage 2 for c (1,30,24), treatment coded 1 is chosen as optimal treatment
decision because it has greater estimated value of Q2, which is 0.3803014 in comparison
to Q2 value from treatment decision -1. Similarly, for stage 1 for c (1,0,34,30), treatment
-1 results in maximum Q1 value of 1.23254, hence, treatment -1 is chosen as optimal
treatment for this stage. So, at last the optimal treatment decision rule can be assigned
as (-1,1) for the patient with covariates c (1,0,34,30) and c (1,30,34), in first and second
stages respectively. Thus, as it can be assumed that different patients have different
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history set so, the model will follow different optimal path resulting the model to be a
personalized treatment regimen model.
4.1.6 Estimating Regime Values
The next comparison that can be done is between the estimated optimal
regime and the standard care decision rule or a constant regime that recommends same
treatment regime for all patients. Thus, the way to do this comparison is by estimating
the value function that is defined as:
𝑉̂ 𝜋 =

∑𝑛𝑖=1 𝑌𝑖 𝕀{𝐴1𝑖 = 𝜋1 (ℎ1𝑖 )}𝕀{𝐴2𝑖 = 𝜋2 (ℎ2𝑖 )}
∑𝑛𝑖=1 𝕀{𝐴1𝑖 = 𝜋1 (ℎ1𝑖 )}𝕀{𝐴2𝑖 = 𝜋2 (ℎ2𝑖 )}

(4.4)

In above equation (4.4), the value Yi is the response for ith patient, (A1i, A2i) are the
randomized treatment decision and (h1i, h2i) are the histories that are observed before
treatment. Thus, the value estimator defined by equation (4.4) is nothing but the
weighted average of outcomes observed from patients in the trial that received
treatment according to the decision rule π. This estimator is also known as the HorvitzThompson estimator [80].
In R-environment, the function value( ) within package iqLearn is used to
estimate the regime values which returns the value estimated of all regimes in the
design. Figure 4.10, below shows the bar graph for the estimated value of each possible
regimens, namely A1A1, A1A2, A2A1 and A2A2.
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Figure 4.13 Estimated regime values for different decision rules

Thus, from above figure 4.13, it can be observed that the regime value for decision
regime A1A1 is very small and that for A1A2 is negative, meaning that the patient’s
health is degrading. The decision rule with maximum regime value is A2A2, so, this
decision rule is assigned as the optimal decision rule and will perform very well for
patient’s well- being if prescribed. Again, for the patient with different set of observed
histories following estimated regime values were obtained:
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Figure 4.14 Estimated regimes values for patient with separate set of observed history

In figure 4.14, all the decision rule can result in the well-being of the patient as no
decision rule has estimated regime value below zero. However, the regime with A2 and
A1 as treatment decisions in stage 1 and stage 2 respectively has the maximum
estimated regime values. Therefore, for this patient with new set of history treatment
regime A2A1 can be considered as the optimal decision rule.
4.2 Discussions
This section of the chapter discusses the results that was obtained above
and how these results can be interpreted for future implementations. So, first the results
were obtained in Data restructuring section, which highlights the importance of
acquiring the training data and remodeling it so that it could be used for training the
model. The raw data that was obtained from Sanford Health needed serious
restructuring so that it can be conducive to SMART design which is an essential part of
the mathematical model. The restructured dataset as shown in figure 4.1, can be easily
implemented for training the model as the input covariates and output response are
clearly defined and available. Similarly, the gender, race, height and treatments which
are randomized in the model are done so that the results explaining relationships
between these predictors to response is obtained during regression analysis.
Next, results were about the multiple regression analysis for both first and
second treatment stages in SMART design. The regression summary tables obtained
are shown on table 4.1 and table 4.2, which gives the values of estimated regression
coefficients, error during the estimation, the residual standard error and quantiles of the
residual. The regression analysis was chosen as the method of inference and the values
obtained from regression summary tables were analyzed for goodness of regression fit.
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These tables not only provide the values of estimated regression coefficients but also
gives the information about ability of regression analysis to account for total variation
in the dependent variable or in other words the quality of fit. The Residual standard
error for stage 2 and stage 1 regression were 0.63 and 1.847, respectively which can be
considered minimal so, as residual standard error is the standard deviation of the
residuals, it’s minimal value results in good quality of regression line fit. Similarly, the
Multiple R-squared value, also known as coefficient of determination is the proportion
of variance in data that is explained by the model and it is proportional to number of
predictor variables. The value of 0.8796 and 0.9549 were obtained for Multiple Rsquared valued in second stage and first stage regression analysis respectively,
indicating that the independent variable explains an estimated 88% variation in
dependent variable of second stage and 95% variation in that of first stage regression.
Therefore, the regression summary table indicated toward good regression line fit and
the estimated values of coefficients can be further used in approximating the Qfunctions.
After the restructured training data was implemented to obtain the
estimated values of regression coefficients and analysis of goodness of fit, the graphical
analysis of residual diagnostics was performed to analyze the fit adequacy of the
regression model and also to check the underlying model assumptions. The assumptions
that are needed to be verified for linear regression are assumptions of linearity,
Homoscedasticity, Independence and Normality. Figure 4.5 and 4.6, shows the residual
versus fitted values plots for second stage and first stage regression analysis
respectively. It can be observed from these plots that the residuals which is the
difference between observed final outcome and predicted outcome from the model, are
not very large as there is not big positive or negative values. Also, to verify the
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assumption of linearity, the residuals from residuals versus fitted values plots are not
too far away or in other words close to 0. Next, the normal Q-Q plots are shown in
figure 4.7 and 4.8 for again second stage and first stage regression analysis respectively.
Usually, the normal Q-Q plots are used to evaluate the normality assumption of linear
regression by comparison of residuals to normal observations. As in both figures (4.7
& 4.8) the observations lie along the 45-degree dotted line, hence, it can be assumed
that the normality assumptions hold in both cases. Similarly, the third plots given in
figures 4.9 and 4.10 shows the scale-location plots which are used for checking the
assumption of homoscedasticity which means there is constant variance in residuals.
Thus, to verify the homoscedasticity assumption it was observed and made sure that
there was no significant trend or pattern in the residuals and as in figures 4.9 and 4.10
the fitted line is approximately horizontal that describes no pattern for both cases,
verifying the assumption of constant variance in residuals. The fourth and final plots in
figures 4.11 and 4.12 are the residual versus leverage plots for second stage and first
stage regression respectively. This plot is used to observe the Cook’s distance which
measures the influence of each observation on the regression coefficients. Thus, it can
be observed in figure 4.11 that the fitted line is flat, and no influential points are
affecting the model, also the cook’s distance for each observation are below 1 and not
significant, indicating lack of influential data points. However, figure 4.12 shows that
the fitted line is somewhat stretched by the influential observations in the dataset,
resulting in significant cook’s distance of those data points which required further
investigation. Although, some influential points are affecting the first stage regression
analysis it does not affect the goodness of fit or fit adequacy of the model as all the
model assumptions are verified.
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Now, after fitting the model to training data and evaluating the
performance by assessing model goodness-of-fit and prediction, the model should be
applied to prescribe treatment rules for future patients. This application can be obtained
either by estimating optimal treatment decision rules as in Table 4.3 or estimating the
regime values, shown in figures 4.13 and 4.14. In Table 4.3, two new patients with
different history set are selected and the values of Q-functions prescribing both
treatment decisions are obtained for these two regression stages. The Q-values for both
treatment decisions are recorded and the one resulting maximum Q-value is selected as
the optimal treatment. In this scenario, the first patient should follow the treatment
regime (-1, 1) and second should follow (-1, -1). Again, figures 4.10 and 4.11 shows
the estimated values of all possible regimes in a bar-plot. Here, the regime with
maximum regime value is selected as optimal decision rule. Thus, from figure 4.10 as
regime A2A2 has highest estimated value, it should be selected as optimal decision rule,
whereas in figure 4.11 which is for another patient, regime A2A1 has maximum
estimated regime value so, it should be selected as optimal decision rule in this case.
Therefore, various statistical analysis was implemented upon the restructured training
dataset and the model performance along with model goodness-of-fit were also
predicted, giving overall good model fit. Hence, the constructed mathematical model
can be used for acquiring prognostic and predictive covariates which can be
implemented for selecting optimal treatment decision rule.
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CHAPTER 5
CONCLUSION AND FUTURE WORKS
5.1 Summary
Personalized medicine emphasizes on the fact that there is a great
variability among individuals which plays a vital role in health and disease control.
Individuals vary from one another in many ways such as the food they it, environmental
factors, DNA and other physical conditions. Thus, the nature of diseases or disease
control also varies from person to person as these factors affect the drug dosage needed
or treatment decisions conducive to treat the disease. Therefore, it is only through
personalized care that the medical institution can provide the right drug to the right
patient for the right disease at the right time with the right dosage. So, it would not be
an overstatement to state that personalized medicine is the future of medicine. Also, for
employing the idea of personalized medicine for prescribing personalized treatment
rules, a mathematical model using statistical inference and machine learning techniques
can serve as a building base for drugs and treatment of the future. Following key things
were considered for building the mathematical model:
•

Acquiring of the training data.

•

Selecting the method of inference based upon clinical covariates and data
dimension.

•

Identification of individualized treatment rules.

•

Linear model fitting to the training data.

•

Evaluation of model performance.

•

Application of model for prescribing treatment rules to future patients.

85
Above listed steps were followed for model building, validation and
implementation process. So, first some part of training data was acquired from Sanford
profile weight management profile dataset. This initial dataset required some critical
restructuring so that it can be used for analysis in two stage SMART design. So, the
covariates were randomized from a comparative trial and BMI of each individual
patients were calculated before, after 4 months and after 12 months of treatment. The
two treatments were coded as either 1 or -1, hence two stages with two treatments at
each stage groups out to four treatment decision rules. Thus, the training data consisted
of 210 rows of patients or observations and 9 columns of covariates.
After acquiring the training dataset, Q-function approximation with
regression analysis was chosen as method of inference to identify the individualized
treatment rule. The model fitting was obtained using multiple regression model and the
model parameters were estimated. Q-learning algorithm, a reinforcement learning
technique that is based upon approximation of Q-functions using regression analysis
was applied for performance evaluation of treatment decisions. Important covariates
that could really impact the patient’s condition were selected as input to the regression
model. The summary tables giving the values of each regression coefficients and value
of error were obtained for regression analysis in two stages of SMART design. Multiple
R-squared values of 88% and 90% were obtained for second stage and first stage
regression analysis respectively.
Further, the model goodness-of-fit was evaluated using residual diagnostic
plots to check if the assumption of linear model is met. From the residual diagnostic
plots the assumptions of Linearity, Homoscedasticity, Independence and Normality
were established for the multiple regression model, fulfilling the conditions and
adequacy of regression fit. Finally, the model was analyzed for prescribing the
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treatment rule to future patients where, first the prognostic and predictive covariates for
new patient was considered and was provided as input to the model. The model output
was Q-values for both treatment stages and the treatment that resulted in maximum Qvalues for both stages was selected as optimal treatment. Hence, the value of each
treatment decision rule was also calculated using Horvitz-Thompson estimator and the
one with maximum estimated regime value was selected as optimal treatment decision
rule.
5.2 Conclusion
In conclusion, a mathematical model was developed and implemented to
prescribe optimal treatment decisions to a patient depending upon his individual
medical covariates. The developed model was used to administer treatments for obese
patients enrolled in Sanford health weight management profile. Application of
reinforcement learning algorithm in Sanford Profile weight management dataset is
unprecedented and through model performance evaluation it can be inferenced that the
model can be applied for prescribing treatment rule for future patients. A minimal
residual standard error of 0.63 and 1.847 was obtained for second stage and first stage
regression analysis respectively. The Q-values for each stage were determined using
the estimated coefficients values from regression equation and the treatment decision
that resulted in maximum Q-value was selected as optimal treatment. For example, a
patient with prognostic covariates of c (1,0,34,30) in first stage of SMART design had
Q-values of 1.023668 and 1.23254 when treatment 1 and -1 was administered
respectively. So, in this case as treatment which is coded as -1 results in maximum Qvalue, it is selected as optimal treatment in that stage. Similarly, same patient with c
(1,30,24) as covariates in second stage had Q-values of 0.3803014 and -0.01900676,
again for treatment 1 and -1 respectively. However, in this case treatment coded as 1
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was chosen to be the optimal one as it resulted in maximum Q-value for that stage.
Lastly, the value estimator was used to estimate the weighted average of each regime
and the bar plots enables to assign the decision rule that results in maximum estimated
regime values as optimal decision rule. Two cases were analyzed for two patients with
different input covariates and it was found that A2A2 and A2A1 were the optimal decision
rule for these patients. Therefore, it can be interpreted that the developed model using
reinforcement learning and function approximation algorithm can be employed in
estimating dynamic treatment regimens for an individual to provide a personalized
healthcare.
5.3 Future Works
Many more modifications and enhancement can be included in above
mathematical model for estimating optimal DTR. First, the training data structure can
be well maintained by constructing a database that stores the values of all essential
covariates such as gender, race, height and weights at fixed intervals. So, Sanford
Health can be suggested to construct a well-maintained database for future use such as
training a mathematical model. Secondly, the problem can be generalized by extending
two stage SMART design to n stage randomization, however, for this scenario there
should be knowledge of covariates value until n stages also, focusing the importance of
data acquisition and database maintenance. Next, the binary nature of treatment
decision can be extended and analyzed where treatment decisions can be coded with
more values than only as 1 and -1, for example a treatment decision can be coded as 0
and applied as an input to the model. Lastly, other regression analysis method such as
non-linear regression can be used and also more robust function approximation
methods can be implemented, for example Q-learning with Mixed Residuals (QL-MR).
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Thus, these future works can further improve the model performance and accuracy for
selecting the optimal treatment decision rules.
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